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SUMMARY 
Successful transplantation requires the prevention of allograft 
rejection and complete reduction of the effects on the immune system by 
any immunosuppressive agent. The commonly immunosuppressive drugs 
used in clinical such as calcineurin inhibitor (tacrolimus, TAC) and 
mTOR inhibitor (sirolimus, SRL) affect naïve T cell
 
differentiation and 
memory T cell expansion; however, the biological and
 
biochemical 
changes induced by these drugs on the generation and expansion of 
different subpopulations of T helper cells are not fully elucidated yet. 
CD4 positive (CD4
+
) T cells are known to orchestrate and regulate 
adaptive immune responses and play an important role in allograft 
rejection or tolerance. CD4
+
 T cells, upon activation and expansion, 
develop into different effector T helper cell subsets and produce distinct 
cytokine profiles and mediate separate effector functions.  From a 
functional perspective, CD4
+
 T cells can be classified into effector T 
helper cells (Th1, Th2, Th17, Tfh) and regulatory T cells (Tregs).  
In the transplant setting, prevailing evidence shows that both effector 
Th1, Th17 cells and cytokines IFN-, IL-17 are involved in the process of 
allograft rejection whereas Treg and Th2 cells favor long-term graft 
survival. The effects of Tacrolimus and Sirolimus on these subsets were 
studied because a balance between graft-destructive effector T cells and 
graft-protective regulatory T cells toward dominance of Tregs may 
promote clinical transplant tolerance. Therapies targeting inhibition of 
pathogenic effector T cells, promotion of Treg cells and directing against 
the mediators of intragraft inflammation may have profound effects on 
the rejection process and induce long-term graft acceptance. 
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In this study, alloreactive CD4
+
 T cells in a MLR culture (Mixed-
Lymphocyte reaction) with responder naïve T cells and allogeneic APCs 
(antigen presenting cells), were generated. Alloreactive CD4+ T cells 
were enriched and restimulated with autologous APCs plus anti-CD3 
stimulation in the absence or the presence of TAC or SRL or their 
combination. Although both TAC and SRL
 
inhibit alloreactive T helper 
cell proliferation
 
and various cytokine productions, the intensity and 
kinetics for TCR-induced
 
T helper subpopulations are markedly 
differently affected between the two drugs. TAC at 2-5ng/ml significantly 
inhibited over 90% of the productions of IFN- and IL-17 from the 
supernatants of bulk cell cultures, and the percentages of IFN- (Th1) and 
IL-17-secreting cells (Th17), whereas SRL at high concentration 
(20ng/ml) had moderate inhibition on IFN- and IL-17 productions (30% 
and 60% respectively). When IL-2 was added to the culture, TAC still 
exerted similar inhibition while SRL completely lost its inhibition on 
IFN- expression. In contrast, in the presence of IL-2, FOXP3 expressing 
cells (Tregs) were markedly increased in SRL treatment compared to the 
controls (Averagely 2-fold increase), whereas TAC treatment was not 
changed and did not show a decreased trend. When the two drugs were 
used in combination, we found that TAC at 2ng/ml with SRL at 2-5ng/ml 
achieved the maximal effect in inhibiting the productions of IFN- and 
IL-17 while maintaining a high level of FOXP3 expression. SRL 
treatment did not affect the plasticity or reprogramming of Tregs, but 
significantly decreased FOXP3
+
IFN- and FOXP3+IL-17+ populations 
when used in combination with very low dose of TAC. When an 
inflammatory setting was mimicking by adding proinflammatory 
cytokines (IL-1, IL-6, TNF-α) to the cell culture, there was a significant 
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decrease of the generation of SRL-derived FOXP3
+
Treg cells. SRL-
derived Tregs expressed normal Treg surface markers, were anergic to 
allostimulations, and functionally suppressed the proliferation of 
allogeneic effector T cells, and Th1 and Th17 alloimmune responses. 
Without affecting FOXO3/FOXP3 interaction, SRL markedly decreased 
DNMT1 expression. DNMT1 is a FOXP3 promoter demethylation  and it 
may account for its long-term induction. Furthermore,  it is a prerequisite 
for stable FOXP3 expression and suppressive phenotype of Tregs. These 
findings can help to guide the clinical use of immunosuppressive drugs to 
promote Treg expansion and to control Th1 and Th17 alloimmunity.  
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RIASSUNTO 
Il successo di un trapianto richiede la prevenzione del rigetto 
d’organo e la completa riduzione degli effetti sul sistema immunitario da 
parte  di qualsiasi agente immunosoppressore. 
I piu’ comuni farmaci immunosoppressori usati in clinica al giorno 
d’oggi, sono gli inibitori della calcineurina (tacrolimus, TAC) e gli 
inibitori mTOR (sirolimus, SRL) che agiscono a livello immunitario sulla 
differenziazione e  l’espansione delle cellule linfocitarie T naïve; però i 
cambiamenti biologici e biochimici indotti da questi farmaci sulla 
generazione e l’ espansione di diverse sottopopolazioni di cellule T helper 
non sono ancora state chiarite completamente.  
Le cellule linfocitarie T CD4 positive (CD4
+
), sono conosciute come 
cellule che regolano la risposta immune adattativa e giocano un ruolo 
importante nel rigetto dei trapianti e nella tolleranza immunologica. 
Queste cellule, mediante attivazione, possono indurre la produzione di 
differenti sottopopolazioni di cellule T effettrici e delle loro differenti 
citochine.  
Le cellule T CD4
+
, dunque,  possono differenziarsi nelle seguenti 
sottopopolazioni: cellule effettrici T helper (Th1, Th2, Th17, Tfh) e 
cellule T regolatrici (Treg).  Nello studio dei trapianti e dei rigetti vi sono 
forti evidenze che mostrano che cellule linfocitarie Th1 Th17 e le loro 
citochine IFN- γ, IL-17 sono coinvolte nel processi di rigetto, mentre 
cellule linfocitarie Treg (T regolatrici) e Th2  e le loro citochine 
favoriscono la sopravvivenza a lungo termine dell’organo trapiantato. 
Considerando che un bilancio, tra le cellule effettrici Th1 Th17 (con il 
ruolo di distruggere e attaccare immunologicamente l’organo trapiantato) 
e le cellule T effettrici Treg e Th2 (con il ruolo di proteggere l’organo 
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trapiantato), potrebbe promuovere lo sviluppo della tolleranza clinica al 
trapianto; studiare  gli effetti di Tacrolimus e Sirolimus su queste quattro 
differenti popolazioni cellulari risulta fondamentale per permettere il 
controllo della risposta imunologica in soggetti trapiantati. 
In questo studio, sono state prima generate cellule alloreattive CD4
+
 T in 
una coltura MLR (Reazione di Mix Linfocitario) con cellule T naïve 
autologhe e APC allogeniche. Le cellule alloreattive CD4
+
 vengono 
ristimolate con cellule autologhe APC autologhe e stimolate con anti-CD3 
in assenza o presenza di TAC,  SRL o entrambi i farmaci. Sebbene sia 
TAC che SRL inibiscano la proliferazione delle cellule alloreattive T 
helper e la produzione di diverse citochine, l’intensità e la cinetica con le 
quali le sottopopolazioni di cellule T sono influenzate e’ differente. TAC 
ad una concentrazione di 2-5ng/ml inibisce significativamente oltre il 
90% della produzione di IFN- e IL-17, prodotti dalle cellule Th1 e Th17, 
mentre SRL utilizzato ad alta concentrazione (20ng/ml) ha un’inibizione 
moderata sulla produzione di IFN- e IL-17  (rispettivamente del 30% e 
60%). Quando IL-2 veniva aggiunto alla cultura cellulare, TAC 
continuava ad esercitare ancora un’ inibizione, mentre SRL perdeva 
completamente la sua inibizione sull’espressione di IFN-. Al contrario, 
in presenza di IL-2, le cellule esprimenti FOXP3 (Tregs) erano piu’ 
numerose (di almeno il doppio) nelle colture trattate con SRL, mentre 
nelle colture cellulari trattate  con TAC non si notava alcuna modifica o 
alcun decremento di cellule Treg. Quando i due farmaci sono stati usati in 
combinazione, utilizzando TAC a 2ng/ml e SRL a 2-5ng/ml, veniva 
raggiunto il massimo effetto nell'inibire la produzione di IFN- e IL-17, 
pur mantenendo un alto livello di espressione di FOXP3. Il trattamento 
con SRL non influenzava la plasticità o riprogrammazione delle cellule T 
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regolatrici (Treg), ma significativamente diminuiva FOXP3
+
 IFN- e 
FOXP3
+
 IL-17
+
 popolazioni quando usato in combinazione con dosi 
molto basse di TAC. Inoltre, quando un ambiente infiammatorio viene 
ricreato con l'aggiunta di citochine proinfiammatorie (IL-1, IL-6, TNF-α) 
nella coltura cellulare, si può notare una diminuzione significativa della 
generazione di cellule Treg FOXP3
+
. Cellule Treg derivanti dalla cultura 
contenenti SRL esprimevano normale marcatori di superficie per le 
cellule Treg, e funzionalmente sopprimevano  la proliferazione di cellule 
T effettrici allogeniche, e le risposte Th1 e Th17 alloimmuni. Senza 
influenzare l'interazione FOXO3/FOXP3, SRL marcatamente riduceva 
l’espressione di DNMT1, che può spiegare la stabilità di espressione di 
FOXP3, in quanto promotore di demetilazione  di FOXP3, sottolineando 
che questo  è un prerequisito per la stabile espressione di FOXP3 e per il 
fenotipo soppressivo delle cellule Treg. In conclusione, questi risultati 
possono aiutare a guidare l'uso clinico di farmaci immunosoppressori per 
promuovere l'espansione di cellule Treg e per controllare la risposta allo-
immune da parte delle cellule Th1 e Th17, considerando inoltre che le 
cellule Tregs sono ritenute fondamentali per la tolleranza immunologica. 
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INTRODUCTION 
 
1.1 Transplantation and the rejection mechanisms 
Transplantation is the act of surgically removing an organ, cells or 
tissue, called a graft, from one individual and placing into a different 
individual. Transplantation occurs because the recipient’s organ has failed 
or has been damaged through illness or injury. The individual who 
provides the graft is called the donor, and the individual who receives the 
graft is called either the recipient or the host. In clinical practice, 
transplantation is used to overcome a functional or anatomic deficit in the 
recipient and this approach to treatment of human diseases has increased 
steadily during the past 40 years, and transplant of kidneys, hearts, lungs, 
livers, pancreas and bone marrow is widely used today. 
There are several different kinds of graft: 
• Autologous graft: tissue transferred from one site on the body to 
another in the same individual 
• Syngeneic graft: tissue transferred between genetically identical 
individuals 
• Allogeneic graft: tissue transferred between genetically 
individuals of the same species  
• Xenogeneic graft: tissue transferred between different species. 
The molecules that are recognized as foreign or allografts are called allo-
antigens, and those on xenograft are called xenoantigens. 
Some of the problems in transplantation are the surgical difficulties 
(largely overcame, now), the graft rejection (still a major problem) and 
the lack of available organs. 
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Alloantigens elicit both cell-mediated and humoral immune responses and 
the major histocompatibility complex (MHC) molecules are responsible 
for almost all strong (rapid) reactions. In fact, MHC molecules play a 
critical role in normal immune responses to foreign antigens, namely, the 
presentation of peptides derived from protein antigens in a form that can 
be recognized by T cells. In fact foreign MHC molecules (especially the 
class I molecules) present a strong barrier to transplant survival, and it has 
been estimated that 5% to 10% of an individual’s CD8 positive (CD8+) T 
cells can recognize and bind fragments of foreign MHC class I. 
So, the recipient immune system recognizes peptide fragments presented 
by MHC class I or II molecules, whether those fragments are derived 
from infectious organisms or from the degradation of self-molecules 
encoded by host genes. In the case of transplanted tissues, the genes of the 
engrafted cells may encode no-self molecules that also can be detected by 
the recipient immune system and function as histocompatibility antigens. 
T cells can be detected and be activated against histocompatibility 
antigens through two different pathways of recognition: direct and 
indirect. 
Direct presentation of alloantigens.  
The direct recognition involves antigen presentation by donor antigen-
presenting cells (APCs) to recipient T cells. Direct recognition can occur 
when some of the MHC class I or II molecules on the donor cells are 
identical to those on recipient cells. Like other cytosolic proteins, MHC 
class I and II molecules can be degraded by proteosomes and the resulting 
fragments presented on the cell surface by intact MHC class I molecules. 
If the donor and recipient have MHC class I molecules in common, APCs 
of donor origin may be able to present those peptide fragments directly to 
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the TCRs of recipient CD8+ T cells. Because the MHC class I molecules 
on the donor cells are the same as those present in the host thymus during 
thymic education, the recipient TCRs are able to recognize and bind the 
pMHC I molecules on the donor cells. Direct recognition may also occur 
if donor APCs ingest cellular debris of donor origin and process/present it 
via MHC class II molecules to recipient to recipient CD4
+
 T cells (Fig.1)  
(Gould and Auchincloss 1999) 
Indirect presentation of alloantigens: 
The indirect recognition involves antigen presentation by recipient APCs 
to recipient T cells. Indirect alloantigeneic recognition occurs when 
allogeneic MHC molecules from graft cells are taken up and processed by 
recipient APCs, and peptide fragments of the allogenic MHC molecules 
containing polymorphic amino acid residues are bound and presented by 
recipient (self) MHC molecules. 
Thus the recognition of foreign histocompatibility antigens and activation 
of the T cells against them involve processes very similar to those 
involved in the initiation of responses against antigens derived from 
infectious organisms. Indeed, the recipient immune system may view the 
transplanted cells as just another batch of infected cells-infected by no-
self genes (Fig. 1) (Gould and Auchincloss 1999)
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B. 
 
    
Figure 1: Direct and Indirect pathway 
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It is possible to say that a major limitation in the success of 
transplantation is the immune response of the recipient to the donor 
tissue, in fact the failure of graft is caused by an inflammatory reaction, 
called rejection. 
Graft rejection occurs when the recipient’s immune recognizes the graft 
as foreign, and destroys it. 
Rejection responses fall into three general categories: hyper-acute, acute, 
and chronic, depending upon timing and intensity. Each type involves 
particular sets of immune responses and is determined in part by the 
genetic mismatch between donor and recipient. 
Hyperacute rejections are the most rapid type of rejection. They are 
initiated and completed within a few days of graft placement, usually 
before the grafted tissue or organs can establish connection with the 
recipient vasculature. In fact, hyperacute rejection is characterized by 
thrombotic occlusion of the graft vasculature that begins within minutes 
to hours after host blood vessels are anastomosed to graft vessels and is 
mediated by pre-existing antibodies in the host circulation that bind to 
donor endothelial antigens (Abbas, Lichtman et al 2011). The immune 
attack is typically mediated (in various situations) by complement, natural 
killer (NK) cells, and/or pre-existing antibodies (Fig.2A). 
Acute rejections occur much sooner after graft emplacement than do 
chronic rejections. The graft establishes vascular connection and function 
normally for a relatively short period of time (e.g., two to four weeks) 
before the first signs of rejection appear. Unlike chronic rejections, acute 
rejections proceed rapidly once underway. Acute rejection is a process of 
vascular and parenchymal injury mediated by T cells and antibodies that 
usually begins after the first week of transplantation. Effector T cells and 
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antibodies that mediate acute rejection develop during a few days or 
weeks in response to the graft, accounting for the time on onset of acute 
rejection. T lymphocytes play a central role in acute rejection by 
responding to alloantigens, including MHC molecules, present on 
vascular endothelial and parenchymal cells. The activated T cells cause 
direct lysis of graft cells or produce cytokines that recruit and activate 
inflammatory cells, which injure the graft (Abbas, Lichtman et al 2011) 
(Fig.2B). 
Chronic rejections are the slowest and the least vigorous type of 
rejection. The transplanted tissue or organs establish a vascular 
connection and proceed to function for weeks, months, and even years 
before signs of deterioration due to immune attack become evident. 
Chronic rejection is characterized by fibrosis and vascular abnormalities 
with loss of graft function occurring during a prolonged period. As 
therapy for controlling acute rejection has improved, chronic rejection has 
emerged as the major cause of allograft loss. The pathogenesis of chronic 
rejection is less well understood that of acute rejection. The fibrosis of 
chronic rejection may result from immune reactions and the production of 
cytokines that stimulate fibroblasts, or it may represent wound healing 
after the parenchymal cellular necrosis of acute rejection. Perhaps the 
major cause of chronic rejection of vascularized organ graft is arterial 
occlusion as a result of proliferation of intimal smooth muscle cells. This 
process is called accelerated (or graft) arteriosclerosis and it is frequently 
seen in failed cardiac and renal allografts (Abbas, Lichtman et al 2011) 
(Fig.2C). 
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C. 
 
 
 
 
 
 
 
 
 
 
Figure 2: Type of graft rejection. A. Hyperacute rejection, B. Acute and C. Chronic. 
Introduction 
 
8 
 
1.2 Immunosuppressive agents in solid organ transplantation 
Effective immunosuppression is an essential pre-requisite for 
successful organ transplantation and improvements in outcome after 
transplantation have to a large extent been dependent of developments in 
immunosuppressive therapy. Immunosuppressive drugs that inhibit or kill 
T lymphocytes are the principal treatment regimen for graft rejection. 
Organ transplantation is now the optimal treatment for many patients with 
end-stage organ failure and national and international registries report 1-
year graft survival rates of around 85% after kidney, liver, and heart 
transplantation (Denton, Magee et al. 1999). 
The current success of organ transplantation is in very large part 
attributable to advances in immunosuppressive therapy and very few 
allograft are now lost as a result of acute rejection. 
A historical perspective on the development of immunosuppression for 
organ transplantation will be analyzed, with a focus of individual 
mechanism of action and efficacy. 
The first successful kidney transplant was in 1954, performed by Murray 
and co-workers, only possible because the donor and recipient were 
monozygotic twins. The immune system was slowly being characterized, 
but there were no effective immunosuppressive agents. The breakthrough 
in chemical immunosuppression for transplantation come with the 
observation that 6-mercaptopurine (6-MP) could induce immunological 
unresponsiveness to a foreign protein (human serum albumin) (Hanidziar 
and Koulmanda 2010). Around the same time, a number of nucleotide 
analogous was created in the hope of finding novel chemotherapy agents. 
One of the compounds, BW57-322 (Azathioprine), stood out in terms of 
efficacy and tolerability. Azathioprine was much less toxic than 6-MP and 
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afforded better prolongation of allograft survival. It rapidly moved into 
clinical use and, while better than total or subtotal body irradiation, it was 
not potent enough to permit most recipients to keep their graft. Also the 
corticosteroids were used to try to prolong graft survival, and it was only 
when corticosteroids were combined with azathioprine in the early 1960s 
that effective chemical immunosuppression became a reality. 
Azathioprine and steroids remained the mainstay of immunosuppression 
for the next 25 years, as efforts were made to develop compounds that 
affected lymphocyte function. It took the discovery of cyclosporine in 
1976 for thoracic organ and liver transplantation to be truly successful. 
Cyclosporine was initially studied for its potential as an anti-fungal 
compound, but when it was discovered to have potent anti-lymphocytes 
properties its development was temporarily halted. Although initially used 
alone, Cyclosporine proved more successful when combined with steroid 
and azathioprine as triple therapy. 
The 1970s were also notable for the development of monoclonal 
antibodies (mAbs), for example, OKT3 (muromonab-CD3), a mouse anti-
human CD3 mAb was used initially to treat acute rejection, and is still 
used occasionally for steroid resistant acute rejection or as a induction 
agent (Schreiber and Crabtree 1992). 
Other two agents with interesting results were identified in the late 1980s, 
namely Tacrolimus (FK506) and Sirolimus (rapamycin). 
And now we will explain their mechanisms of action:  
Calcineurin inhibitors (CNIs) Cyclosporine and Tacrolimus are 
licensed for use in organ transplantation. The molecular mechanisms 
whereby CNIs inhibit T cell activation are well understood. T cell 
receptor engagement with donor MHC/peptide normally triggers calcium-
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dependent intracellular signaling resulting in activation of 
calcium/calmodulin-dependent phosphatase calcineurin (Fig.3). This 
leads to the dephosphorylation of NF-AT allowing translocation into the 
nucleus where it enhances binding of transcription factors to genes 
encoding for pro-inflammatory cytokines such as IL-2, IL-3, IL-4, IFN- 
and TNF-α. After entering the cytoplasm, CNIs form complexes with 
their immunophilins. Cyclosporine binds to cyclophilin and tacrolimus 
bind to the 12 kDa FK506-binding protein (FKBP-12). The CNI-
immunophilins complex, inhibits the calcineurin activity, and hence 
prevents nuclear translocation NF-AT and cytokine gene transcription. 
The net result is that CNIs block the production of cytokines such as IL-2 
and inhibit T cell activation and proliferation, which so it leads to a 
reduced function of both effector T cells and Tregs (Schreiber and 
Crabtree 1992; Demirkiran, Hendrikx et al. 2008). 
The introduction of cyclosporine into clinical practice ushered in the 
modern era of transplantation. 
Before the use of cyclosporine, the majority of transplanted hearts and 
livers were rejected, but now the majority of these allografts survive for 
more than 5 years. 
Sirolimus and Everolimus (The mTOR inhibitors) belong to the group 
of immunosuppressive agents called mammalian target of rapamycin 
(mTOR) inhibitors. Both drugs are macrocyclic lactones, with Sirolimus 
being a naturally occurring fermentation product of the actinomycete 
Streptomyces hygroscopicus, while Everolimus represents a chemical 
modification of sirolimus to improve absorption. Sirolimus (SRL) and 
Everolimus (EVL) bind to the 12 kDA intracellular immunophilin FK506 
binding protein (FKBP12) but, unlike Tacrolimus, do not inhibit 
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calcineurin activity. Instead the SRL/FKBP12 and EVL/FKBP12 
complexes are highly specific inhibitors of mammalian target of 
rapamycin (mTOR). MTOR is a serine/threonine kinase involved in the 
phosphadyt-inositol 3-kinase (P12K)/AKT (protein kinase B) signaling 
pathway (Fig.3). Inhibition of mTOR has a profound effect on the cell 
signaling pathway required for cell-cycle progression and cellular 
proliferation. mTOR inhibitors directly bind the mTOR Complex 1 
(TORC1) and inhibit the PI3K/AKT/mTOR signaling, which is part of 
CD28 costimulatory and IL-2 receptor signaling pathways known for 
fully T cell activation, thus results in decreased phosphorylation 
mTOR/p70S6 kinase and 4E-BP BP (Abraham and Wiederrecht 1996). 
Long-term treatment with mTOR inhibitors also affects TORC2, which is 
required for fully activation of AKT kinase (Sarbassov, Ali et al. 2006; 
Janes, Limon et al. 2010). Activation of AKT via PI3K/AKT/FOXO 
signaling may directly phosphorylate FOXO family transcription factors, 
subsequently excludes them from the nucleus, and thus diminishes their 
coactivating function for de novo FOXP3 induction whereas the 
PI3K/AKT/mTOR signal phosphorylation of p70S6K and 4E-BP1 may 
account for its anti-proliferation effect on effector T cells (Ouyang, 
Beckett et al. 2010; Merkenschlager and von Boehmer 2010) with an 
increasingly important role for mTOR in directing T cell activation and 
differentiation has become apparent. Further dissecting the underline 
mechanisms for the induction/expansion Tregs by mTOR inhibitors and 
the environmental effects on the differentiation, activation and 
proliferation of CD4 Th cells may develop novel strategies to prevent 
graft rejection and promote the induction of tolerance to the transplant  
(Mitchell, Afzali et al. 2009; Li and Turka 2010; McMurchy, Bushell et 
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al. 2011). So, combinations of cyclosporine (which blocks IL-2 synthesis) 
and rapamycin (which blocks IL-2 driven proliferation) are potent 
inhibitors of T cell responses. 
 
 
 
Figure 3: CNI vs mTOR inhibitors  
Mechanisms of action of maintenance immunosuppressive agents. CNIs (ciclosporin 
and tacrolimus) bind to their respective immunophilins, and inhibit calcineurin. 
Calcineurin is then unable to dephosphorylate NFAT, which will prevent translocation of 
NFAT to the nucleus and thereby production of IL-2. Sirolimus is an mTOR inhibitor. It 
binds to FKBP and inhibits mTOR, which in turn inhibits transition of the cell cycle 
from G1 to S phase. MPA and LFL are also cell-cycle inhibitors, and act via inhibition 
of nucleotide synthesis. Abbreviations: CNI, calcineurin inhibitor; FKBP, FK506-
binding protein; IL-2, interleukin-2; LFL, leflunomide; MHC, major histocompatibility 
complex; MPA, mycophenolic acid; mTOR, mammalian target of rapamycin; NFAT, 
nuclear factor of activated T cells; TCR, T cell receptor. 
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1.3 Functional diversity of helper T lymphocytes (Th1 Th2 Th17) 
Despite the dramatic advances of modern immunosuppression in 
reducing acute graft rejection, long-term allograft survival has remained 
disappointing. The current pharmacological agents that so effectively 
prevent acute graft rejection are inadequate for averting late graft loss 
caused by chronic rejection. The mechanism of action of most of these 
agents is based on preventing T cell activation and/or proliferation, but no 
drug directly targets the differentiation of CD4
+
 effector T cells. 
Until recently, it was believed that there were two distinct types of 
effector CD4
+
 T helper (Th) cells based on the types of cytokines they 
produced when stimulated to differentiate (Abbas, Murphy et al. 1996) 
Th1 cells, which produce large quantities of Interferon-γ (IFN-γ), 
considered to be the major mediators of allograft rejection, and, Th2 cells 
characterized by the production of Interleukin-4 (IL-4), IL-5, and IL-13 
have been proposed to favor long-term graft survival in some models. 
However, the validity of the Th1/Th2 paradigm in transplantation has 
been questioned. More recently, a new Th cell subtype was identified that 
produced IL-17 and was also found to mediate allograft rejection in T-bet 
knockout recipients of bm12 cardiac grafts (O'Shea and Paul 2010). 
Moreover, a regulatory CD4
+
 T cell phenotype (Treg) was also 
discovered with dominant production of IL-10 and TGF-β, associated 
with marked capability of suppressing pathogenic effector T cells in the 
transplant setting. From a functional perspective, CD4 T cells can be 
classified into effector T helper cells (Th1, Th2, Th17, Tfh) and 
regulatory T cells (Tregs) (Fig.4).  
In sum, immune homeostasis in transplantation seems to be the result of 
the balance among different T helper subtypes. 
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In the transplant setting, prevailing evidence shows that both effector 
Th1, Th17 cells and cytokines IFN-γ, IL-17 involve in the process of 
allograft rejection whereas Treg and Th2 cells favor long-term graft 
survival although it is not currently possible to draw any conclusions 
regarding a specific role for these cells (Strom and Koulmanda 2009; 
Mitchell, Afzali et al. 2009; Li and Turka 2010; Wood, Bushell et al. 
2011) therefore, a balance between graft-destructive effector T cells and 
graft-protective regulatory T cells toward dominance of Tregs may 
promote clinical transplant tolerance (McMurchy, Bushell et al. 2011). 
On the other hand, the environmental factors, especially pro-
inflammatory cytokines, prevent the commitment of donor-activated T 
cells into Treg lineage, instead they foster generation of the Th1/Th17 
phenotypes. In addition, the inflammatory milieu may disarm existing 
Treg cells, converting them into inflammatory effector T cells, or may 
render them resistant to suppression. Therefore, therapies targeting 
inhibition of pathogenic effector T cells, promotion of Treg cells and 
directing against the mediators of intragraft inflammation may have 
profound effects on the rejection process and induce long-term graft 
acceptance (Hanidziar and Koulmanda 2010; Li and Turka 2010). 
Recent data has shown that Cyclosporin A (CsA) blocks IL-15-mediated 
production of IL-17 in the joints of rheumatoid arthritis patient. CsA 
inhibits activity of human IL-17 promoter via NFAT as a crucial sensor of 
TCR signaling in the IL-17 promoter (Mitchell, Afzali et al. 2009). 
Further, CsA decreased CD3 induced IL-17 production in a dose 
dependent manner (Li and Turka 2010). Sirolimus (SRL) has been 
reported to selectively expand both murine and human functional natural 
Tregs in vitro while depleting CD4
+
CD25
- 
effector T cells. On the other 
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hand, SRL but not CsA permits thymic generation and peripheral 
preservation of murine Tregs (Wood, Bushell et al. 2011). Further, SRL-
conditioned dendritic cells are poor stimulators of allogeneic CD4+ T 
cells, but enrich for antigen-specific Foxp3
+
 T regulatory cells and 
promote murine cardiac tolerance. Using reporter mice for Treg marker 
FOXP3, demonstrated that SRL promotes de novo conversion of 
alloantigen-specific Treg cells, whereas CsA completely inhibits this 
process. Upon transfer in vivo, converted Treg cells potently suppressed 
the rejection of donor but not third party skin grafts. Thus, the differential 
effects of SRL and CsA on Teff and Treg cells favor the use of SRL in 
shifting the balance of aggressive to protective type allo-immunity. 
SRL, by inhibiting mTOR activity, blocks almost completely, mitogen 
and cytokine-induced proliferation of T effector cells. However, its effect, 
as stated above, on the inhibition of proliferation is less profound in 
CD25hi Tregs, and in following mitogenic activation they survive and by 
selection expand (Hippen, Merkel et al. 2011). The reason for these 
differential effects of SRL on each T cell subset is uncertain, but potential 
mechanisms have been suggested. One proposed explanation is that the 
PI3K/Akt/mTOR pathway is activated to a lesser extent in Treg cells after 
activation with IL-2, in comparison to conventional T effector cells, and 
therefore that Treg cells use alternative survival pathways independent of 
mTOR (Hippen, Merkel et al. 2011; Tresoldi, Dell'Albani et al. 2011). 
Interestingly, it has also been suggested that activation of the 
PI3K/Akt/mTOR pathway may even be detrimental to the function of 
Tregs. Indeed, when Akt is overexpressed in naïve T cells, the expression 
of FoxP3 is inhibited after stimulation with TGF-β and IL-2. It is 
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therefore possible that the PI3K/Akt/mTOR pathway may inhibit the 
differentiation of T cells into regulatory CD4
+
 T cells. 
 We are now starting to recognize how different classes of 
immunosuppressive agents can differentially alter the alloimmune 
responses. It is then imperative to study how different 
immunosuppressive agents can modulate the immune system so that 
appropriated combinations and/or modifications of immunosuppressive 
drugs can be used to prevent graft loss due to rejection or to chronic 
calcineurin inhibitors (CNIs) nephrotoxicity.  
 
 
 
 
Figure 4: New paradigm for T helper cell differentiation. 
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1.4 Scientific hypothesis and aim of the work 
Despite the improvements in immunosuppression leading to a 
reduction in acute rejection rates, long-term allograft survival remains 
disappointing. CD4+ T helper cells are known to orchestrate and regulate 
adaptive immune responses and play a key role in allograft 
rejection/tolerance. From a functional perspective, they can be classified 
into CD4+ effector T cells (Th1, Th2, Th17) and CD4
+
 regulatory T cells 
(Treg). While IFN-γ producing effector T cells are major mediators of 
graft rejection (Th1), Th2 cytokine producing T cells and Treg have been 
considered protective of the allograft. More recently, IL-17-producing 
cells were also demonstrated to be involved in allograft loss. 
Based on that, we may conclude that the outcome of the allograft is 
dependent on the balance among these different T cell subtypes and 
manipulation of T helper cell differentiation might permit increased graft 
acceptance.  
Little is known about the impact of immunosuppressive drugs on human 
allospecific T cell subpopulations. In this work we will generate different 
subpopulation (Th1, Th17 and Treg) of human alloreactive CD4
+
 T cells 
and test the effects of mTOR inhibitors vs CNIs alone and in different 
combination on the generation of Th1, Th17 and Treg cells. We will also 
study, in the system, the role of inflammatory cytokines in altering the 
balance of Tregs towards Th1/Th17.   
In this study, we were interested in how alloactivated T cells responded to 
immunosuppressive agents and their differentiation/expansion to different 
T cell subsets and exerted their functions in alloimmunity. 
By assessing in vitro cytokine production by alloreactive CD4
+
 T helper 
subsets from healthy donors, it will be possible to show that although both 
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TAC and SRL
 
inhibited alloreacitve T helper cell proliferation
 
and 
various cytokine productions, the intensity and kinetics for TCR-induced
 
T helper subpopulations are differently affected between the two drugs.  
Using an in vitro system, we will study the effects of mTOR inhibitors vs 
CNIs alone and in different combination on the generation of Th1, Th17 
and Treg cells. The hypothesis is: mTOR inhibitors cause a differential 
effects on human Th1, Th17 and Treg compared to CNIs and the 
combination of these two immunosuppressive agents tested at different 
concentrations will allow us to achieve a maximal effect in controlling 
Th1 and Th17 responses while maintaining and sparing Treg function 
subsets (Hippen, Merkel et al. 2011; Tresoldi, Dell'Albani et al. 2011). 
Furthermore, if SRL decreased the expression of DNMT1, which can 
epigenetically modify DNA methylation in the FOXP3 locus, this drug 
might account for a gradual accumulation of the FOXP3
+
 population and 
a suppressive phenotype of Tregs in this system (Huehn, Polansky et al. 
2009; Josefowicz, Wilson et al. 2009; Daniel, Wennhold et al. 2010).
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MATERIALS AND METHODS  
 
2.1 Reagents 
Sirolimus (SRL) and Tacrolimus (TAC) were obtained from 
Axxora (San Diego, CA). Recombinant human IL-1β, IL-6 and TNFα and 
IL-10 neutralizing antibody were purchased from R&D system 
(Minneapolis, MN). Anti-CD3 monoclonal antibody (UCHT1) and anti-
CD28 monoclonal antibody (L293) were obtained from BD Biosciences 
(San Diego, CA). Anti-CD3/CD28 coated microbeads were obtained from 
Invitrogen (Carlsbad, CA). PMA (phorbol 12-myristate 13-acetate), and 
Ionomycin (Ionomycin calcium salt from Streptomyces conglobatus), 
EDTA (Ethylenediaminoetracetic acid disodium salt) and LPS were 
obtained from Sigma-Aldrich (St. Louis, MO). Culture medium RPMI 
1640 1x with L-glutamine, PBS 1x (Phosphate-Buffered Saline), 
Lymphocyte Separation Medium, Sodium-Pyruvate, MEM (non-essential 
aminoacids) were provided by Mediatech, Inc. 1M Hepes Buffer in 
normal saline, 2-Mercaptoethanol were purchased from VWR. MACS 
Separation columns (LS columns), CD14 Microbeads human, CD4 
Microbeads human, CD45 Microbeads human were provided by MACS 
Miltenyi Biotech. Human Regulatory T cell staining Kit (Ache some 
antibody) were provided by eBioscience. FBS (fetal bovine serum) was 
provided by ATLAS biological 
2.2 Cell culture 
Medium RPMI 1640 with L-glutamine was supplemented with 
10% heat-inactivated FCS (HyClone Laboratories),
 
100 U/ml 
penicillin/100 µg/ml streptomycin, 2 mM
 
L-glutamine, 10 mM HEPES, 1 
mM
 
sodium pyruvate, 1x nonessential amino acids, 0.05mM β-
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mercaptoethanol (all from MediaTech). The cell cultures were incubated 
at 37°C in an atmosphere of 5% CO2. 
2.3 Magnetic isolation of monocytes and T cell subsets 
PBMC were isolated by
 
Ficoll-Hypaque gradient centrifugation of 
heparinized venous
 
blood obtained from a group of 30 healthy volunteers. 
The Informed
 
consent was obtained from each subject, and research 
protocols were approved by the Institutional Review
 
Board of 
Northwestern Memorial Hospital in accordance with regulations
 
mandated by the Department of Health and Human Services. 
Cells recovered from the gradient interface were washed one time at 2000 
rpm and twice at 1200 rpm, with RPMI 1630. 
All isolations of monocytes and T
 
cell subsets were performed using 
magnetic beads and reagents
 
from Miltenyi Biotec. The buffer for 
monocytes and T
 
cell subsets selection washing was 1xPBS pH 7.2, 0.5 % 
FBS, 2mM EDTA.  
CD14
+
 monocytes were first isolated from PBMC by
 
immunomagnetic 
positive selection of CD14
+
 and the flow through was used for CD45RA
+
 
naïve T cell selection (CD14
+
 and CD45RA
+
 Cell Isolation
 
kits) 
according to the manufacturer’s instructions. Memory-like CD45RO+ T 
cells were purified from the primary culture by depletion of 
CD45RA
+
cells and positive selection of CD4
+
 T cells (CD4+ cell 
isolation kit), CD4
+
CD25highCD127

 Tregs were purified from SRL-
treated monocyte/T cell culture (see below). The purity of each separated
 
population was assessed by immunofluorescence flow cytometry,
 
and the 
purity was >95% in all
 
experiments. 
 
 
Materials and Methods 
 
21 
 
2.4 MLR culture 
As we have discussed, graft rejection is often a mediated process 
that is initiated by recognition of allogeneic MHC molecules. The mixed 
leucocytes reaction (MLR) is a useful in vitro model of direct T cell 
recognition of allogeneic MHC gene products and is used as a predictive 
test of cell/mediated rejection. MLR is induced by culturing mononuclear 
leukocytes cells (which include T cells, B cells, natural killer cells, 
mononuclear phagocytes, and dendritic cells) from one individual with 
mononuclear leukocytes derived from another individual, and in humans, 
these cells are typically isolated from peripheral blood. (Abbas, Lichtman 
et al. 2011)  
Purified CD4
+
CD45RA
+
 naïve T cells (1.5 x 10
6
/well) and allogeneic 
CD14+ cells (7.5 x 10
5
/well) were co-cultured for 7 to 11 days in 24-well 
culture plates in complete RPMI 1640. Effector/Memory
 
CD45RA
-
 T 
cells were then purified and rested for overnight.  
2.5 Secondary Monoyte/T cell culture 
Alloresponsing memory-like CD4
+
CD45RA

 T cells (1 x 
10
5
/well) co-cultured with 100ng/ml of soluble anti-CD3 antibody and 
autologous CD14 cells (0.5 x 10
5
/well) in 96-well U-bottom plates in the 
presence or absence of 100U/ml IL2 and for 5-6 days. In some 
experiments, TAC, SRL, or the combinations of the two agents were 
added at the beginning of the cultures. Different inflammatory cytokines 
IL-1 (10ng/ml), IL-6 (20ng/ml), or TNF- (50ng/ml) were added alone or 
in combination in the presence of TAC or SRL or the combinations of the 
two agents. 
2.6 Cell surface and intracellular staining  
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In these experiments, in the monoyte/T cell culture, cells were 
restimulated with 20ng/ml PMA and 500 ng/ml ionomycin
 
for 6 h. During 
the last 4 h, GolgiStop (BD biosciences)
 
was added to cultures to prevent 
cytokine secretion. 
Cells were first stained for surface markers with fluorochrome-conjugated 
CD4,
 
CD25, CD127, CD45RO, CTLA-4, GITA Abs (all from BD 
Biosciences). For intracellular IFN-γ and IL-17 staining, cells were 
followed fixed and permeabilized with a BD Cytofix/Cytoperm 
Fixation/Permeabilization Solution Kit and incubated
 
with PE-conjugated 
anti-IL-17 and FITC-conjugated anti-IFN (all from BioLegned). For 
intracellular FOXP3 staining, after appropriate surface staining, cells 
were fixed and permeabilized with eBioscience Human Regulatory T cell 
Staining Kit and incubated
 
with FITC-anti-IFN- γ, -IL-10 and PE-anti-IL-
17, TGF-β (R & D system) and PE-Cy5-conjugated anti-FOXP3 
(PCH101) or primary rabbit anti-DNMT1 (sc-20701, Santa Cruz, CA) for 
30 min at 4°C followed with PE-anti-rabbit Ig together with PE-Cy5-
FOXP3. For phosflow staining of phospho-FOXO3a and phospho-AKT, 
at the end of monoyte/T cell culture, cells were harvested, washed and 
fixed for 10 min at 37°C using Cytofix buffer (BD Biosciences), pelleted, 
and permeabilized in PERM III buffer (BD Biosciences) for 30 min on 
ice. The cells were washed twice in staining buffer (BD Biosciences) and 
rehydrated for 30 min on ice in the staining buffer. Cells were stained 
with anti-pFOXO3a (Ser253) antibody for 30 min at room temperature. 
Washed twice and were restained with FOXP3–PE-Cy5, anti-pAKT 
(Ser473)–PE or anti-rabbit-Ig–PE antibodies for 30 min at room 
temperature. Data were acquired on a FACSCalibur flow cytometer and 
analyzed by FlowJo software (Tree Star, Ashland, OR). 
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The flow cytometer is an instrument that can be used to analyze specific 
cell populations.  One or two laser, as well as light detectors, are used to 
gather information about the cells as they are acquired.  To gather 
information about each cell individually, the flow cytometer uses 
hydrodynamic focusing to prevent multiple cells from passing through the 
laser at the same time.  In short, the cell sample is in a fluid that is 
injected into the center of a cylinder of sheath fluid from the flow 
cytometer.  As they move forward, their path narrows, causing the cells to 
line up in a row to pass in front of the laser.  Two properties of the cells 
that can be investigated are size and granularity (complexity).  The size of 
the cells is measured by the Forward Scatter (FSC) of the light as it 
passes through the cell.  The granularity (complexity) is measured by the 
Side Scatter (SSC) of the light as it passes through the cell.  Figure 4 
illustrates the laser light passing from left to right and being deflected to 
the forward or side light detectors (Fig.5). 
 
 
Figure 5.  Forward and Side Scatter  
 
In addition to cell size and complexity, additional light detectors can 
measure the light emission from stains used to label the cells.  The 
Side Light Detector  
Cell Complexity 
Forward Light Detector 
Cell Size 
Laser 
Light 
Source 
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fluorochromes used in these stains are excited by the laser, and emit a 
different wavelength of light.  When using several stains, their 
fluorochromes are all excited by the same laser, but they emit different 
specific wavelengths of light from each other, allowing the light detectors 
to detect each stain individually.  Using the data collected, plots and 
histograms can be used to identify and analyze cell populations of 
interest. 
When reading the data output from the flow cytometer, the first plot you 
will want to look at is Forward Scatter (FSC) vs. Side Scatter (SSC).  As 
showed in Figure 6, there are several populations of cells (clusters of 
dots) that are present.  It will be important to know which population the 
cells you are interested in looking at are located in order to proceed. 
 
 
Figure 6: Several populations of cells reading the data output from the flow 
cytometer 
 
Lymphocytes 
Monocytes 
Neutrophils 
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From the FSC vs. SSC plot, you will want to ‘Gate’ on the population that 
your cells of interest are in.  Gating on a population simply means that 
you are selecting the cells that you want to look at in future plots.   
2.7 Cytokine assays 
The cytokine assays is commonly used to detect and quantify 
cytokine from different samples is Flow cytometry combining 
intracellular cytokine staining, to investigate either the spontaneous 
production of cytokines or the stimulated (i.e.) induced production of 
citokines, and multiparameter flow cytometry allows for simultaneous 
detection of two or more cytokines in a single cells of the lineage defined 
by expression of one or more surface markers. (Prussin 1997) 
Citokine flow cytometry is an antibody-based technique amenable to 
signal amplification by biotinylation of the reagents. Its specificity and 
sensitivity are strictly dependent on anticytokine antibodies selected for 
use. 
Supernatants
 
were collected on day 6 of monocyte/T cell cultures and 
stored at -80°C.  Cytokine secretions from the supernatants were 
quantified with flowcytomix cytokine assay kit (eBioscience) as per the 
manufacturer’s instructions. Approximately 2,000-gated events were 
collected on a Beckman Coulter CMP500 flow cytometer, and 
FlowCytomix Pro 2.4 software (eBioscience) was used for data analysis. 
2.8 Quantitative real-time PCR analysis 
In molecular biology, real-time polymerase chain reaction, also 
called quantitative real time polymerase chain reaction (Q-
PCR/qPCR/qrt-PCR) or kinetic polymerase chain reaction (KPCR), is a 
laboratory technique based on the PCR, which is used to amplify and 
simultaneously quantify a targeted DNA molecule. For one or more 
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specific sequences in a DNA sample, Real Time-PCR enables both 
detection and quantification. The quantity can be either an absolute 
number of copies or a relative amount when normalized to DNA input or 
additional normalizing genes. 
The procedure follows the general principle of polymerase chain reaction; 
its key feature is that the amplified DNA is detected as the reaction 
progresses in real time. This is a new approach compared to standard 
PCR, where the product of the reaction is detected at its end. Two 
common methods for detection of products in real-time PCR are: (1) non-
specific fluorescent dyes that intercalate with any double-stranded DNA, 
and (2) sequence-specific DNA probes consisting of oligonucleotides that 
are labeled with a fluorescent reporter which permits detection only after 
hybridization of the probe with its complementary DNA target. 
Frequently, real-time PCR is combined with reverse transcription to 
quantify messenger RNA and Non-coding RNA in cells or tissues (Logan 
J, Edwards K et al. 2009).  
In this experiment, for the quantitative real time PCR, total RNA samples 
(2 μg)  was extracted from cells using the RNeasy Mini Kit (Qiagen, 
Valencia, CA) according to the manufacturer’s instructions. The first 
strand of cDNA was obtained using High Capacity RNA-to-cDNA kit 
and transcripts were
 
quantified by real-time quantitative PCR using 
TaqMan Fast Universal PCR kit on an ABI 7500 Fast Real-Time PCR 
System (all RT-PCR reagents from Applied Biosystems, Foster City, 
CA). Human transcription factors T-bet (Hs00203436_m1), RORgt 
(Hs01076112_m1), GATA-3 (Hs00231122_m1), and FOXP3 
(Hs00203958_m1) predesigned Gene Expression Assays also from 
Applied
 Biosystems were used according to the manufacturer’s 
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instructions. Reactions were carried out using TaqMan Universal PCR 
Fast Master Mix and the following amplification conditions: 95°C for 10 
min, 40 cycles of 95°C for 3 sec, and 60°C for 30 sec. Specific gene 
expression was normalized to the
 
housekeeping genes GAPDH. 
Expression of specific mRNA
 
levels was calculated by first determining 
the average threshold
 
cycle (Ct) for each culture, which corresponded to 
the following:
 
(average specific gene threshold cycle – average GAPDH 
threshold cycle). Triplicate samples were used to calculate
 
the average 
threshold cycle. The replicate threshold cycle (Ct)
 
was then calculated 
with the following formula: (Ctwith drug
 – Ctwithout drug). Transcription factors 
T-bet, RORgt, GATA-3, and FOXP3 mRNA were expressed
 
as 
expression fold value (2
–Ct
).
 
 
2.9 Suppression assays 
CD4
+
CD25
+
CD127
–
 Tregs from the monocyte/T cell culture 
treated with 10 µg/ml SRL were purified with magnetic bead separation. 
The capacity of the Tregs to suppress T cell responses were assessed by 
their addition (at increasing cell doses) to a newly set-up co-cultures of 
CD4
+
CD25
– 
responder (5 x 10
4
) stimulated with original donor or third 
party irradiated PBMC stimulators (1 x 10
5
; 3000 rad, 
137
Cs source) in 
complete RPMI1640 medium. Original donor group vs. the third party are 
set for testing allospecific suppression. Two methods were applied for the 
evaluation of suppressive capacity. In the first series of experiments 
CFSE dilution technique was used. CFSE (Carboxyfluorescein 
succinimidyl ester) dilution technique is a technique where CFSE labeling 
infuses cells with a dye that is diluted during successive rounds of cell 
division. Facs analysis of CFSE labeled cells provides an assay to identify 
the number of cell division that cell populations under go following 
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stimulation up to 8 generations CFSE is used for staining cells prior to 
flow cytometric analysis of cell proliferation or cell division. This dye can 
be used to monitor lymphocyte proliferation, both in vitro and in vivo, 
due to the progressive halving of CFSE fluorescence within daughter cells 
following each cell division(Lyons and Parish 1994; Xu, Zhang et al. 
2008).  Techniques currently available for determining cell division are 
able to show one or, at best, a limited number of cell divisions. This 
technique, in which an intracellular fluorescent label, is divided equally 
between daughter cells upon cell division. The technique is applicable to 
in vitro cell division, as well as in vivo division of adoptively transferred 
cells, and can resolve multiple successive generations using flow 
cytometry. The label is fluorescein derived, allowing monoclonal 
antibodies conjugated to phycoerythrin or other compatible 
fluorochromes to be used to immunophenotype the dividing cells. 
In this experiment, CD4
+
CD25
–
 responder cells were labeled with CFSE 
and then activated for 7 days by stimulators with addition of various 
numbers of PKH26 labeled Treg cells. Tregs were labeled with PKH26 (a  
red fluorescent dye that can, in principle, be used for the study of 
asymmetric cell divisions) aiming to separate their potential proliferation, 
which may affect the responders proliferation readout. Alternatively, 
suppressive capacity was assessed with thymidine incorporated 
proliferation assay for 7 days by adding 3H-Thymidine for the last 12-18 
hours. Background proliferation was determined
 
from cultures with 
CD4
+
CD25
– 
T effectors alone and CD4
+
CD25
+
CD127
– 
Treg cells alone.  
2.10 Western blotting analysis 
At the end of culture, cells were washed and lysed, 50 μg of 
proteins were loaded and separated on SDS-PAGE, and western blot was 
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done as described  from Xu L, Immunol Lett 2008; Xu, Zhang et al. 2008.  
The following antibodies were used in this study: rabbit polyclonal anti-
DNMT1 (H-300, Santa Cruz, CA), anti-phospho AKT (Ser473), and anti-
phospho FOXO3a (Ser253) (both from Cell Signaling Technologies, 
MA).  
2.11 Statistical analysis 
Data were analyzed by Student’s two-tailed t test. A value of p < 
0.05 was considered statistically significant. Data are presented as 
mean ± SD. 
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RESULTS 
 
3.1 Alloreactive naïve CD4
+
CD45RA
+
 T cells can differentiate into 
effector Th1, Th17 and Treg cells 
Subpopulation of Th1, Th17 and Treg cells and their signature 
cytokines IFN-γ, IL-17, and the forkhead box transcription factor 
(FOXP3) are best documented for their relation to acceptance and 
rejection of transplanted organs (Mitchell, Afzali et al. 2009; Strom and 
Koulmanda 2009). Most studies on the differentiation/expansion of Th 
cell subsets have used strong anti-CD3/CD28 stimulation and 
inflammatory settings by modulating levels of polarizing cytokines in 
vitro or in vivo, but this approach might not be ideal to evaluate the 
physiologic role of T cell subsets during immune responses (Li, Kim et al. 
2010). We studied the differentiation and functions of alloreactive 
effector Th1, Th17 or Treg cells in the absence of exogenous polarizing 
cytokines or insults, and tested the role of immunosuppressive agents 
affecting the differentiation/expansion processes and their possible 
clinical relevance to the transplantation.  
Human naïve CD4
+ 
CD45RA
+ 
 T cells purified from ex vivo PBMCs were 
CFSE-labeled and co-cultured with allogeneic APCs or CD14
+
 
monocytes, which include myeloid CD14
+
 monocytes and CD11
+ 
dendritic cells for 9-11 days. At the end of culture, we tested the IFN-γ, 
IL-17 and FOXP3 expressing cells with intracellular staining method. We 
found that CD4
+
CD45RA
+
 naïve T cells can differentiate into alloreactive 
effector IFN- γ+/Th1, IL-17+Th17 and FOXP3+/Treg subsets at single cell 
level (Fig. 7A), and the proliferated cells were found to gain the most 
expression of IFN- γ, IL-17 or FOXP3 than non-dividing cells. As human 
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Th17 differentiation from naïve T cells needs more strict conditions, in 
addition to TGF-β and IL-6, they need additional cytokines like IL-23 and 
IL-21, which are not secreted by monocytes, but activated T cells (Zhou, 
Ivanov et al. 2007; Volpe, Servant et al. 2008; Yang, Anderson et al. 
2008), so we did not expect to see much IL-17 secretion from these cells 
and, as predicted, we saw very few IL-17-secreting alloresponsive T cells 
in the culture (Fig. 7A, 1% of CD4
+
 T cells expressing IL-17 cultured 
with monocytes). As control, when autologous APCs were used as 
stimulators in the primary cultures, we saw few CD4+T cells upregulated 
CD45RO expression in conjunction with IFN-γ, IL-17 or FOXP3 
expression to differentiate to alloresponsive T cells (data not shown).  
Alloresponsive T cells are defined as T cells proliferating in response to 
allogeneic APCs, and the cell population changes and their phenotypes 
are defined by expression effector/memory-like marker CD45RO
+
. 
Further analysis by cell surface staining of CD45RO (human memory T 
cell marker) vs. CD45RA (human naïve T cell marker) showed that these 
cells highly expressed CD45RO
+
 and this depends on the cell stimulation 
conditions. Compared to more strong stimulation by a classic MLR, 
CD4
+
CD45RA
+
 naïve T cells co-cultured with allogeneic APCs have a 
delay expression of CD45RO
+
, but can be induced to a maximum 
expression similar to the classic MLR at day 9 (Fig. 7B). From these 
experiments, it can be concluded that human CD4
+
CD45RA
+
 naïve T 
cells can differentiate into effector Th1, Th17 and Treg cells in a similar 
way as classic MLR by the stimulation with allogeneic APCs. 
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A. 
    
 
 
 
B.  
           
 
 
 
Figure 7. Alloreactive naïve CD4
+
CD45RA
+
 T cells can differentiate into effector 
Th1, Th17 and Treg cells.   Naïve CD4+CD45RA+ T cells labeled with CFSE co-
cultured with allogeneic CD14+ monocytes. 
A. The proliferated CD4 T cells (CFSE low) were capable to produce cytokine IFN- of 
Th1, IL-17 of Th17 and to express transcription factor FOXP3 of Tregs and to 
differentiate into effector CD4 T cell subsets. Upper panel: at day1; Lower panel: at 
day7.  
B. After co-cultured for 9 days, 7412% of naïve CD45RA+T cells (open circles) were 
activated and expressed CD45RO+ marker, which is similar to a classic MLR (open 
squares). 
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3.2 APC, TGF-β and IL-2 are essential for the 
differentiation/expansion of alloreactive CD4
+
CD45RA
 
T cells into 
effector Th17 and Treg cells 
To study how alloreactive effector/memory CD4 T cells were 
affected by different immunosuppressive drugs as these types of cells are 
enriched in the blood circulation and intragraft in post-transplant 
recipients, we isolated viable alloresponsive effector/memory-like 
CD4
+
CD45RA
  
T cells from the above culture by depleting unstimulated 
CD45RA
+
 and positively recovering CD4
+
 cells. Cells were cultured in 
complete RPMI 1640 medium and rested overnight for subsequent 
experiments.  
With regard to mechanisms, it is believed that TCR (T cell receptor) 
together with co-stimulation signal plus various cytokines are required for 
the induction of Th cell subsets. Fresh monocytes were most efficient in 
inducing Th17 from both memory and naïve T cells (Evans, Suddason et 
al. 2007; Crome, Clive et al. 2010; Kryczek, Wu et al. 2011) while in vivo 
induction of functional suppressive Treg was best achieved by 
subantigenic activation of T cells under conditions that avoid functional 
activation of APCs. In addition, it was shown that in human alloreactive 
CD4
+
 T cell are biased to a Th17 response, which is inversely related to 
the number of HLA class II mismatches (Litjens, van de Wetering et al. 
2009). In these regards, to mostly mimic physiologic environment, we 
stimulated alloreactive CD4 T cells with submitogenic dose of anti-CD3 
(e.g. 100ng/ml) in the absence or the presence of costimulatory signal 
from monoclonal anti-CD28 or autologous APCs for 5-6 days. The results 
showed that strong activation of alloreactive CD45RA

 T cells by anti-
CD3 plus CD28 beads induced higher expression of both IFN-γ+ and 
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FOXP3
+
 cells, with conversely a lower percentage of IL-17-secreating 
cells. In contrast, anti-CD3 plus autologous APCs induced significant IL-
17 production than those of anti-CD3 alone or anti-CD3 plus anti-CD28 
in the absence of APCs (Fig. 8A, and data not shown). The data suggested 
that under non polarizing conditions, efficient differentiation/expansion of 
Th17 cells relies on the presence of APCs (Evans, Suddason et al. 2007; 
Allan, Crome et al. 2007), and transient high FOXP3 expression by anti-
CD3 plus anti-CD28 in conjunction with IFN- γ secretion, which accounts 
for high percentage of IFN- γ+FOXP3+ double positive T cells (1.7% vs. 
10.6% for anti-CD3/APC vs. anti-CD3 plus anti-CD28), are contrast to 
the induction of functional Treg cells. Finally, we tested TLR ligands, 
which mimic pathogenic stimulation, and we found that strong activation 
of monocytes by both TLR4 ligand (LPS) and TLR7/8 (R848) induced 
prefunded activation of IFN-γ-producing Th1 cells with accordingly 
lower levels of IL-17-producing Th17 cells (data not shown).  
It is known that TGF-β is indispensible for in vitro induction of iTreg 
cells (Induced T regulatory), and IL-2 is required for the expansion and 
survival of Treg, both in vitro and in vivo (Davidson, Di Paolo et al. 
2007; Chen, Kim et al. 2011). As previous data argued that medium with 
fetal bovine serum contains TGF-β, our culture medium contains 3ng/ml 
of TGF-β, too. We therefore continued to use this culture medium without 
adding extra TGF-β. Then, we checked the effect of IL-2 in our system. 
In the presence of normal levels of IL-2 (e.g., 20U/ml), CD4
+
IFN-γ+ and 
CD4
+
IL-17
+
 cells were increased from average of 15.5% to 22.1% and 
6% to 11.8% respectively while higher levels of IL-2 (100U/ml) slightly 
decreased the percentages of CD4
+
IFN- γ+ and CD4+IL-17+ cells (Fig. 
8B). The reason may be that high amount of IL-2 induced more apoptosis 
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to effector T cells (Refaeli, Van Parijs et al. 1998). Of note, previous 
studies showed contrary results for IL-2 in the differentiation of Th17 
cells. IL-2 may inhibit Th17 differentiation, or only attenuates IL-17 
production without inhibiting its differentiation, or instead is required for 
Th17 differentiation (Deknuydt, Bioley et al. 2009). Considering that IL-2 
is necessary for the initial development and survival of memory effector T 
cells, thus, the overall influence of IL-2 on the Th17 differentiation 
program may be more complex than anticipated. In the presence of high 
levels of IL-2 (100U/ml), FOXP3
+
 cells were significantly induced up to 
12.9% in culture (Fig. 8B). This confirmed that high concentration of IL-
2 is required for the induction and stability of FOXP3 expression and the 
survival and expansion of FOXP3
+
Treg cells (Chen, Kim et al. 2011). It is 
to be noted that a small fraction of IFN- γ+FOXP3+ and IL-17+Foxp3+ 
cells was existed in our system, and again, in contrast to the induction of 
IFN-γ+FOXP3+ cells, autologous APCs are needed for inducing 
appreciable levels of IL-17
+
Foxp3
+
 T cells without exogenous cytokines 
(Figure 10D and data not shown) (Crome, Clive et al. 2010; Kryczek, Wu 
et al. 2011). Thus, from the above results, optimal induction of Th1, Th17 
and Treg cells in our system required weak TCR stimulation plus APCs 
and the concomitant presence of IL-2 and TGF-β.  
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A. 
 
B. 
 
 
Figure 8. APC, TGF- and IL-2 are essential for the differentiation/expansion of 
alloreactive Th1, Th17 and Treg subsets in monocyte/T cell culture.  Purified 
alloreactive memory-like CD4+CD45RAT cells generated from allogeneic activated 
naïve CD4+CD45RA+ T cell as in Figure 1 (without CFSE labeling) were rested 
overnight and re-stimulated with soluble anti-CD3 and autologous APCs (thereafter as 
monocyte/T cell culture) or anti-CD3/CD28 beads in the presence of IL-2 for 5 to 6 
days. The induction of IFN-+/Th1, IL-17+/Th17 and FOXP3+/Treg cells were tested by 
intracellular staining of IFN-, IL-17 or FOXP3 proteins.  
A. APCs were essential for the induction of IL-17-secreating Th17 cells or FOXP3+Treg 
cells in monocyte/T cell culture compared to anti-CD3/CD28 stimulation which induced 
higher transient expression of FOXP3 with barely affected IL-17-secreating Th17 cells.  
B. IL-2 was differently needed for the induction of IFN-+Th1, IL-17+Th17 and 
FOXP3+Treg cells. High concentrations of IL-2 (> 100U/ml) were specifically required 
for the induction of FOXP3+Tregs.  * p < 0.05 compared to No IL-2 treated group. 
Values represented mean ± SD and were obtained from 4 healthy donors. 
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3.3 Calcineurin inhibitor and mTOR inhibitor differently inhibit Th1 
and Th17 cells in alloreactive CD4 T cells 
Calcineurin inhibitors (CsA, TAC) and mTOR inhibitor (SRL, 
Rapalogs) have been used for a long time for the treatment of graft 
rejection and have proved to inhibit the activation of conventional 
effector T cells in both naïve and memory compartments. We started to 
check how alloreactive CD4
+
 T cells, defined here as effector/memory-
like CD4
+
CD45RA

 cells, are affected by these two immunosuppressive 
drugs in the generation and expansion of Th1 and Th17 cells. Again, in 
contrast to the previous work with strong TCR/CD28 stimulation of both 
naïve and memory CD4 T cells under polarizing conditions, we 
stimulated alloreactive CD4
+
CD45RA

 cells with subantigenic anti-CD3 
(100ng/ml) in the presence of autologous APCs with or without TAC or 
SRL for 5 days and systemically we determined IFN-γ and IL-17 
production at both single cell level by intracellular staining and bulk 
culture supernatants with multiplex cytokine assay. We found that TAC at 
low dose (2ng/ml), blocked over 90% of the productions of IFN- γ and 
IL-17, even in the presence of high concentration of IL-2 (100U/ml). In 
the contrary, SRL at high concentration (10ng/ml) had moderate 
inhibition on IFN- γ and IL-17 productions (30% and 60% respectively, 
Fig 9A). Interestingly, this inhibition of IFN- γ production by SRL but not 
TAC was reversed in the presence of high concentration of IL-2 (Figure 
9B). The combination of the two drugs showed significantly inhibition on 
both IFN- γ and IL-17 productions (N= 6-8 donors, * p < 0.05; ** p < 
0.01). 
In parallel experiments, we examined the cytokine production of 
supernatants collected from bulk culture with different treatments. 
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Compared with the supernatants collected from TAC or SRL or the 
combination of the two treated cells, we found that in agreement with 
intracellular staining, TAC strongly blocked IFN-γ production, while SRL 
showed more profound inhibition of IFN-γ compared to intracellular 
staining (Fig. 9C). This is obvious that other immune cells such as IFN- γ 
-secreting monocytes in our system could be inhibited by SRL. As we 
could not detect any IL-17 production in the supernatants collected from 
monocyte/T cell culture in the absence of IL-2, we determined IL-17 
production in our system in the presence of IL-2. Both TAC and SRL 
inhibited IL-17 production although in this situation. TAC was less 
efficient in blocking IL-17 production as compared to intracellular 
staining (Fig. 9C). The reason for this discrepancy maybe is because TAC 
has minor effect on monocytes than on T cells, as such monocyte 
produced Th17 polarizing cytokines IL-1β and IL-6 play a role for the 
high percentage of IL-17+Th17 cells (Zhou, Ivanov et al. 2007); and also 
because in the presence of high amount of IL-2, calcineurin inhibitor may 
reverse activated T cells from activation-induced cell death and IL-21, IL-
23 produced by these cells are important for the induction of Th17 cells. 
These results, together with the intracellular staining at single cell levels, 
suggest that TAC is more efficient than SRL to inhibit differentiation and 
expansion of preformed alloreactive CD4 T cells. At molecular levels, 
TAC blocks T cell activation signaling and subsequently production of T 
cell survival cytokine IL-2, and SRL most likely affects IL-2-induced 
later G1-S cell cycle transition in T cells, thus prevents their proliferation 
and favor the establishment of T cell anergy, or prevents T cell anergic 
reversal by the presence of IL-2 (Powell, Lerner et al. 1999).  
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A.    
       
B.    
        
C.   
 
Figure 9. TAC and SRL potentially inhibit IFN- and IL-17 producing cells in 
monocyte/T cell cultures.  Purified alloreactive CD4+ CD45RA T cells (1 x105/well) 
generated from allogeneic activated naïve CD4+ CD45RA+ T cell as in Figure 8 were 
rested overnight and re-stimulated with low dose of anti-CD3 (100ng/ml) and autologous 
APCs (0.5 x105/well, thereafter as monocyte/T cell culture) in the absence or in the 
presence of 100U/ml of IL-2 for 5 to 6 days. TAC, SRL or the combination of the two 
drugs at indicated concentrations were added at the start of cultures. At the end of 
culture, the cells were harvested, and intracellular cytokines were stained at single cell 
levels.   
 At the end of culture, the cells were harvested, and intracellular cytokines were stained 
at single cell levels.   
A. No IL-2 was added to the monocyte/T cell culture.  
B. In the presence of 100 U/ml of IL-2. Values represented mean ± SD and were 
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obtained from 6–8 healthy donors. * p < 0.05; * * p < 0.01 compared to no treatment 
C. Cytokine productions from bulk culture supernatants collected from the same 
monocyte/T cell cultures were determined with flow-based multiplex cytokine assay.  
 
3.4 Restimulation of alloreactive CD4 T cells in the presence of SRL 
leads to increased FOXP3 expression 
TAC and SRL inhibit proliferation and differentiation of 
conventional T cell in both naïve and memory T cell compartments 
(Demirkiran, Hendrikx et al. 2008), but the results in this study showed 
that only SRL favors Treg cells generation and expansion (Coenen, 
Koenen et al. 2006; Strauss, Whiteside et al. 2007). In this system, the 
SRL and TAC were tested directly on the Treg generation from 
alloreactive CD4
+
 T cells. Given that the expression levels of both 
FOXP3 and CD25 are proportional in human FOXP3
+
 T cells, and 
FOXP3 is a more specific marker than CD25 for Treg cells, we first 
tested different combinations of Treg markers for detecting this 
population in our system. In pilot experiments, we found that various 
amounts of SRL (0.5 to 20ng/ml) parallel increased similar percentages of 
CD4
+
FOXP3
+
 cells compared to CD4
+
CD25
+
FOXP3
+
 cells in the 
presence of IL-2 in our monocyte/T cell culture. So we used % of 
CD4
+
FOXP3
+
 cells instead of % of CD4
+
CD25
+
FOXP3
+
 T cells as Treg 
readouts for the remaining experiments (Kryczek, Wu et al. 2011); and 
data not shown). We next started out to check how alloreactive T cells 
defined here as CD4
+
CD45RA

 cells were affected by these two 
immunosuppressive drugs. We restimulated rested alloreactive 
CD4
+
CD45RO
+
 T cells with soluble anti-CD3 mAb (100ng/ml) in the 
presence of autologous APCs with rhIL-2 (100U/ml), and SRL or TAC or 
the combination of the two at indicated concentration for 5 days. At the 
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end of culture, the cells were harvested and analyzed by flow cytometer 
for Foxp3 expression. In the absence or normal culture condition of IL-2 
(no more than 20U/ml), both SRL and TAC have no significant effects on 
the expression of FOXP3 in our culture system (data not shown). This 
also proved that IL-2 is needed for the steady expression of FOXP3 and 
the survival of FOXP3+ Tregs (Figure 8B. In the presence of IL-2 
(100U/ml), the percentage of FOXP3 expression in SRL-treated Tregs 
was increased significantly in comparison with those in the medium only 
(26.6%5.7 vs. 14.1%5.3; n=6; p<0.05), whereas TAC-treated iTregs were 
not changed or showed a decreased trend (Figure 10A). When used in 
combination at low doses, TAC at 2ng/ml with SRL at 2-5ng/ml achieved 
the maximal effects in inhibiting the productions of IFN-γ and IL-17 
while maintaining a high level of FOXP3 expression (Fig. 10A and Fig. 
10B). From the same culture as above, the absolute cell number of T cells 
recovered by counting trypan-blue negative cells was markedly reduced 
in T cells exposed to TAC and SRL compared with control cultures 
(average fold expansion: 0.3 ± 0.2 in TAC cultures vs. 1.1 ± 0.4 in SRL 
cultures vs. 3 ± 1.2 in medium cultures; n = 6) (Figure 10B). Taken 
together, proliferation of alloreactive T cells is reduced in the presence of 
SRL, yet, the percentage of FOXP3
+
CD4 T cells is increased in our 
system, supporting the previous data that SRL favors Treg expansion by 
binding to mTOR complex and selectively blocking proliferation of 
AKT/mTOR-sensitive effector T cells while sparing Tregs (Bensinger, 
Walsh et al. 2004; Crellin, Garcia et al. 2007).  
We also tested whether there were also any changes at transcriptional 
RNA levels. Expression of specific T cell subset transcription factor T-bet 
(Th1), GATA3 (Th2), RORγt (Th17) or FOXP3 (Tregs) at mRNA levels 
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was determined by real-time PCR. In agreement with the flow cytometry 
data, in the presence of IL-2 (100U/ml), SRL at 5ng/ml had little effects 
on T-bet and GATA3 while moderate inhibition on RORγt mRNA 
expressions. TAC at low dose (2ng/ml) effectively blocked both T-bet 
and RORγt mRNA expressions (Fig. 10C). As for FOXP3 mRNA 
expression, SRL augmented while TAC moderately inhibited its 
expression, and the combination of the two showed an increase of its 
expression (Fig. 10C). 
 
 
A.                                                            B.                
                         
 
C. 
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  D. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Restimulation of alloreactive CD4 T cells in the presence of SRL leads to 
increased FOXP3 expression. Purified alloreactive CD4+CD45RA- T cells (1 x105/well) 
generated from allogeneic activated naïve T cell as in Figure 8 were rested overnight and 
re-stimulated with low dose of anti-CD3 (100ng/ml) and autologous APCs (0.5 
x105/well) in the presence of 100U/ml of IL-2.  
A. At the end of culture, the cells were harvested and intracellular FOXP3 expression 
was stained at single cell levels. (* p < 0.05 and a p > 0.05 compared to no treatment). 
Values represented mean ± SD and were obtained from 6–8 healthy donors. 
B. TAC and SRL inhibited the proliferation of alloreactive CD4+CD45RA T cells. Cell 
growth was assessed by manual counting at the end of cultures. There was a significantly 
higher amount of cells recovered in medium cultures than those in TAC or SRL cultures 
(** p< 0.01, *** p< 0.001 compared to medium). Values represented mean ± SD and 
were obtained from 4 healthy donors. 
C. Effects of TAC and SRL on the lineage-defining transcription factor expressions for 
T cell subtypes. Real-time PCR were performed to determine gene specific transcription 
factors for T cell differentiation, e.g. transcription factor T-bet for Th1, RORt for Th17, 
and FOXP3 for Treg differentiation. The results were normalized to the housekeeping 
genes GAPDH and shown here as fold changes. Values represented mean ± SD and were 
obtained from 3 separate donors with quadruplicates. 
D. Low concentration of SRL (e.g. 5ng/ml) alone did not increase percentage of IFN-
+FOXP3+, IL-17+FOXP3+ or IFN-+IL-17+ T cell subsets. However, SRL at this 
concentration plus very low concentration of TAC (e.g. 1ng/ml) significantly inhibited 
the production of these three T cell subsets (*p < 0.05, ** p < 0.01 compared to control). 
Values represented mean ± SD and were obtained from 6–8 healthy donors. 
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3.5 SRL together with very low dose of TAC inhibits the induction of 
IFN-γ+FOXp3+ and IL-17+FOXP3+ Treg subsets 
In addition to nTreg (Naturally occurring regulatory T) and iTreg 
(Induced T regulatory) subsets, there is evidence of phenotypic and 
functional heterogeneity and plasticity within the FOXP3
+
 Treg 
population, which potentially include IFN-γ+FOXP3+ and IL-17+FOXP3+ 
cells (O’shea jj science 2010), and has been implicated as the pathologic 
effector T cells in autoimmune inflammatory diseases and in cancers, but 
incomplete data in transplantation settings (Kryczek, Wu et al. 2011; 
Hippen, Merkel et al. 2011). As a consequence, we wondered whether 
SRL-derived alloreactive FOXP3
+
Tregs in our system also contained 
significant IFN-γ+FOXP3+ and IL-17+FOXP3+ cells. Thus, we tested the 
IFN-γ and IL-17-producing cell content in SRL treated cells vs. control 
group. Although we only detected low amount of IL-17
+
FOXP3
+
 or IFN- 
γ +FOXP3+ cells present in the alloreactive CD45RA- T cells irrespective 
of the presence of SRL compared to the controls (Fig. 10D), more 
importantly, SRL-treated group did not show any increase of IL-
17
+
FOXP3
+
 or IFN-γ +FOXP3+ cells. Furthermore, SRL together with 
very low dose of TAC diminished significantly the percentage of these 
Treg subpopulations. Considering other recent data that showed these 
small populations of induced or expanded Treg subsets still possessed 
suppressive function both in vitro and in vivo in a GVDH model, and the 
most important aspect of SRL-treated Tregs that display the same % of 
FOXP3
+
 cells and are plasticity resistant to further exposure to Th17 
polarizing cytokines and possesses a regulatory activity as good as those 
prior to Th17-cell condition exposure TGFβ+IL-21+IL-23 (Hippen, 
Merkel et al. 2011; Tresoldi, Dell'Albani et al. 2011). These results 
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showed that SRL inhibits the differentiation and growth of IL-17
+
Treg or 
IFN- γ+Treg cells in our system, and we may conclude that a clinically 
practical application of SRL-derived Tregs for future adoptive Treg-based 
therapies in transplantation. 
3.6 Production of TGF-β and IL-10 in Tregs and monocyte/T cell 
culture  
Although Treg cell-mediated suppression is not fully understood, 
anti-inflammatory cytokines TGF-β and IL-10 represent one of multiple 
means for them to accomplish suppression of different inflammatory 
responses (Vignali, Collison et al. 2008). To examine whether SRL 
affects cytokine production from Treg cells, intracellular staining of TGF-
β and IL-10 in FOXP3+Tregs and TGF-β and IL-10 productions in the 
supernatants of monocyte/T cell culture treated with SRL, were measured 
after 5 days. There was no significant difference in TGF-β production 
from both FOXP3
+
Treg cells and supernatants of cell culture among the 
control and SRL-treated groups (data not shown), whereas IL-10 
production slightly decreased with SRL-derived Treg cells by 
intracellular staining compared to untreated controls. In consistent with 
our Treg-MLR suppressive assay, it also showed that although IFN- γ, IL-
17 productions from the culture supernatants were significantly inhibited, 
TGF-β was not affected (Figure 12.1A). In sum, soluble TGF-β and IL-10 
are not important factors for their suppressive function by SRL-derived 
Tregs. 
3.7 IL-1β, TNF-a, and to a lesser extent IL-6 down-regulate FOXP3 
expression in alloreactive CD4 T cells 
Cytokines have seemed increasingly important for the induction, 
regulation and function of distinct Th subsets in addition to antigen 
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strength and type of costimulation. TGF-β plus IL-2 are essential for the 
induction of iTreg (Davidson, DiPaolo et al. 2007; Horwitz, Zheng et al. 
2008; Chen, Kim et al. 2011), whereas TGF-β plus IL-6 or TGF-β plus 
IL-21 or IL-1β or TNF-α are recently shown involved in differentiation/ 
expansion of human Th17 cells from both naïve, and memory CD4
+
 T 
cells (Volpe, Servant et al. 2008; Yang, Anderson et al. 2008). During 
early inflammatory process, the acute phase cytokines IL-1β, IL-6 and 
TNF-α are produced and they are important mediators of early 
inflammatory events in allografts that undermine graft survival. In this 
regard, we determined the effects of these important proinflammatory 
cytokines on the generation of Th1/Th17, Treg cells were certain because 
our culture media contain about 3ng/ml of TGF-β, which is similar 
amount for the most in vitro study for both Treg and Th17 cell inductions. 
Because the primary purpose for the current study is to induce appropriate 
amount of Th1, Th17 and Treg cells aiming to test any effect by IS 
(immunosuppresor) drugs, we did not add extra exogenous TGF-β to our 
culture system. Alloreactive CD4
+
CD45RA

 T cells were stimulated for 5 
days with subantigenic dose of anti-CD3 in the presence of autologous 
APCs and varied of concentrations of TAC and SRL. Three cytokines 
(10ng/ml of IL-1, 50ng/ml of TNF-α, and 20 to 100ng/ml of IL-6) were 
added individually or in the combinations at the beginning of culture. 
IFN-γ, IL-17 and FOXP3 expressions were determined by intracellular 
staining and flow cytometry. In the first set of experiments for individual 
cytokines, IL-1, but not IL-6 (up to 100ng/ml) could augment the 
productions of IFN-γ and IL-17, while TNF-α could only show a minimal 
effect on IFN-γ production (Fig. 11A and 11B). A combination of these 
three components, however, increased about 41% of IFN- γ+ or 23% of 
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IL-17
+
 cells compared to the control (Fig. 11A and 11B). Under the above 
inflammatory conditions, low doses of TAC or the combination of low 
doses of TAC and SRL still effectively blocked over 90% of IFN- γ or IL-
17 production, while SRL alone moderately inhibited IFN- γ production 
or to a less extent for IL-17 production (Fig. 11A and 11B). The data 
showed here that IL-1β is a stronger stimulus while IL-6 alone has little or 
no effect on human naïve or memory T cells, consistent with previous 
human work (Yang, Anderson et al. 2008). The data in this study may 
also prove previous conclusion that IL-6 may need IL-23 to promote the 
differentiation/expansion of Th17 cells (Liu, Lin et al. 2004). TNF-α may 
exert its role through enhancement of IL-6 to induce Th17 cells, but we 
cannot rule out the possibility that TNF-α stimulates APCs to produce IL-
6 and IL-23 for Th17 cell induction (Iwamoto, Iwai et al. 2007). 
In the presence of above each single inflammatory cytokine (IL-1β, IL-6 
or TNF-α), FOXP3 expression in CD4+ T cells was marginally affected, 
but it was significantly down-regulated in the presence of all three 
cytokines compared to the absence of these cytokines in monocyte/T cell 
culture (Figure 11C, 11.93.2% vs. 6.083.01%, p< 0.05).  
At molecular levels, these results are consistent with previous data that 
IL-6 may through IL-6/Stat3 downregulated FOXP3 expression or IL-6 
induced re-methylation of CpG residues and decreased AcH3 in the 
upstream enhancer of the FOXP3 gene, thereby inhibiting FOXP3 
expression. TNF-α may inhibit the expansion and function of Tregs via 
TNFRII which shown higher expression on Treg than Teff cells 
(Valencia, Stephens et al. 2006). Given the fact that TNF-α blockade 
constitutes one of the major therapeutic options in the treatment of some 
chronic inflammatory diseases in humans, such as rheumatoid arthritis 
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and inflammatory bowel disease, the above results make the role of TNF-
α in Teff/Treg crosstalk even more important to understand. Finally, 
simultaneous activation of naive T cells and Treg cells in the presence of 
APCs under neutral condition, or directly stimulation of naïve Tregs in 
Th17-polarizing condition induced the differentiation of Tregs into IL-17 
producing cells, and IL-1β was mandatory for this function as IL-1R 
highly expressed on Tregs than on naïve T cells (Deknuydt, Bioley et al. 
2009; Li, Kim et al. 2010). We concluded that proinflammatory 
environment reverent to the downregulation of FOXP3 expression are 
necessary to be reconsidered for the future adoptive Treg-based therapies 
(Li and Turka 2010; O'Shea and Paul 2010). 
In this condition, SRL at 5ng/ml still can significantly increase 
CD4
+
FOXP3
+
 Treg though the percentage was lower than that induced by 
the same concentration of SRL without the presence of any above 
cytokines (Fig. 11C). When used in combination, low doses SRL at 
5ng/ml and TAC at 2ng/ml still showed an increased expression of 
FOXP3 compared to a decreasing expression of FOXP3 with the 
treatment of TAC alone though the difference did not reach a statistical 
level (Fig. 11C).  
Of note, conventional effector T cells activated in the presence of strong 
co-stimulatory signals or in pro-inflammatory microenvironments are 
refractory to Treg cell-mediated suppression (Beriou, Costantino et al. 
2009; Crome, Clive et al. 2010). According to the results, FOXP3 
expression is downregulated by the presence of proinflammatory 
stimulation as well as the presence of pro-inflammatory cytokines IL-1β 
and IL-6 can induce human Treg cells to secrete pro-inflammatory 
cytokines and concomitantly affect the ability to suppress (Beriou, 
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Costantino et al. 2009), it is likely as important to control inflammation as 
to consider inducing transplantation tolerance in alloimmunity. 
Considering that SRL-derived Tregs did not increase IFN- γ+FOXP3+ and 
IL-17
+
FOXP3
+
 cells (Figure 10D) and its anti-inflammatory properties, 
SRL prove to be an ideal choice for clinical transplantation.  
 
 
A.                                                                
 
 
B.   
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Figure 11. TAC and SRL differently affect the generation of T cell subsets in the 
presence of inflammatory cytokines in monocyte/T cell cultures.  
A and B In the presence of proinflammatory cytokines (10ng/ml IL-1, 20ng/ml IL-6 or 
50ng/ml TNF-; 3CKs were the combination of the above three individual cytokines), 
TAC still effectively blocked IFN--producing cells (A) and IL-17-producing cells (B) 
while SRL was less effective to do so although inflammatory cytokines increased the % 
of both Th1/Th17 cells (*P<0.05; ** P<0.01 vs. 3CKs; b P<0.05 vs. none). Values 
represented mean ± SD and were obtained from 4–6 healthy donors.  
C. In the presence of proinflammatory cytokines as in A and B, the percentage of 
FOXP3+Tregs was significantly decreased (b P<0.05 vs. none). Addition of SRL 
recovered most of Tregs (*P<0.05 vs. 3CKs) although the percentage was lower than 
that induced by the same concentration of SRL without the presence of any above 
cytokines (Figure 5C, P<0.05). The combination of the two drugs had a higher % of 
Tregs than TAC alone though the difference did not reach a statistical level (a P>0.05 vs. 
3 CKs). Values represented mean ± SD and were obtained from 4–6 healthy donors.  
 
3.8 CD4
+
CD25
+
CD127
–
 Tregs derived from SRL treated group suppress 
T cell proliferation and the differentiation of Th1 and Th17 subsets 
The phenotypic changes between the control and SRL-treated 
culture were analyzed. SRL-derived FOXP3
+ 
Tregs from the monocyte/T 
cell cultures showed typically phenotypic markers of regulatory T cells, 
they expressed memory marker CD45RO and lacked the expression of the 
IL-7 receptor
 
-chain CD127. SRL-treated Tregs also expressed higher 
level of CTLA-4 more than untreated controls, while expressed 
glucocorticoid-induced tumor necrosis factor receptor (GITR) at similar 
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levels compared to the control (Supplementary Figure S6). In addition, 
the expression levels of FOXP3 in CD4
+
 cells from SRL-treated group 
were higher than that in CD4
+
 cells compared to the control (Figures 10A 
and 10D).       
Furthermore, we tested whether the Foxp3
+
 population of SRL-derived 
Tregs has a suppressive function. We isolated CD4
+
CD25
high
CD127
−/low
 
cells from Tregs as a FOXP3
+
-enriched population, and found that over 
90% of CD4
+
CD25
+
CD127
-/low
 cell population isolated from SRL-treated 
Tregs expressed regulatory marker FOXP3. 
As shown in Fig. 12A, CD4
+
CD25
+
CD127
−/low
 cells derived from the 
culture treated with SRL showed significant suppression of proliferation 
of CD4
+
CD25

 T responder cells at a various range of ratio of Treg to 
responder T cells (Tresp). Of note, SRL-derived Tregs specifically and 
more efficiently inhibited allogeneic responder T cells at low ratio 
(Treg:Tresp < 1:5, Figure 6A, left panel). When this ratio increased, e.g 
Treg:Tresp = 1:2, SRL-Tregs showed a non-alloantigen specific 
suppression (Fig. 12A). This is reasonable as the presence of high 
numbers of Tregs, more anti-inflammatory cytokines (such as TGF-β, IL-
10 or IL-35) produced by the Tregs and exerted non-specific suppression. 
In a separate assay, responder CD4
+
CD25
−
T cells were labeled with 
CFSE and co-cultured with irradiated donor specific or a third party 
PBMCs plus a similar range of ratio of PKH26 labeled SRL-Tregs to 
responder T cells (Tresp) and co-cultured for 7 days. Responder T cell 
proliferation was determined by the dilution of CFSE in proliferated cells. 
The results demonstrated a dose-dependent inhibition of proliferation of 
CD4 T cells by SRL-Tregs (Fig. 12B, upper panel). The inhibition of 
alloresponse Th1 and Th17 immunity in the presence of SRL-derived 
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Tregs was detected by intracellular staining of IFN-γ and IL-17-secreating 
cells. The results showed that RL-Tregs effectively inhibited the 
alloresponse Th1 and Th17 activation (Fig. 12B). Finally, we checked the 
IFN- γ and IL-17 productions in the co-culture supernatants of above 
conditions, and found that in consistent to the cytokine secreting at single 
cell level, the production of these two cytokines were also blocked by the 
presence of SRL-derived Tregs (Fig. 12C).  
 
A.                                                                
 
 
B.  
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C.  
 
FIGURE 12. SRL-derived FOXP3+ Tregs from the monocyte/T cell cultures maintain 
a normal suppressive activity.   
A. Normal suppressive properties of SRL-derived Tregs. Fresh CD4+CD25−responder T 
cells (Tresp) (5 × 10
4
/well) and purified CD4
+
CD25
+
CD127
−/low
 cells from SRL (10 
ng/ml) treated group (1 × 103/well to 2.5 × 104/well) were co-cultured with irradiated 
allogeneic PBMC or a third-party at a Tregs/Tresp cell ratio of 1:2, 1:10 or 1:50, 
respectively. After 5 d of culture, responder T cell proliferation was determined using 
[3H]-thymidine incorporation (left, raw data). The inhibition of responder proliferation 
by SRL-derived Tregs was expressed relative to that of responder T cells alone (right, 
percentage). The proliferation of Tregs was 424 ± 101 cpm. The control value 
(proliferation of responder alone) was 10,200 ± 1,403 cpm. Each value (cpm) was 
calculated by subtracting the proliferation (cpm) of SRL-treated Treg alone.  
B. SRL-derived Tregs dose-dependently inhibited Th1 and Th17 alloimmune responses 
by detecting IFN- and IL-17-secreating cells. The results also demonstrated a dose-
dependent inhibition of proliferation of CD4 T cells by CFSE dilution profile. 
C. IFN- and IL-17 productions in the culture supernatants were also blocked by the 
presence of SRL-derived Tregs at Treg/Tresp cell ratio of 1:2. Values are the mean SD  
of at least of three experiments. Statistical analysis was performed using the Student t 
test. **p < 0.01 vs. control.  
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A. 
 
 
 
 
 
 
 
B.    
 
 
Supplemetal figure 12.1.  
A. Phenotypic analysis of SRL-derived Tregs. Rested alloreactive CD4+CD45RA-- T 
cells (5×105/well) were cultured with soluble anti-CD3 mAb (100ng/ml) in the presence 
of autologous APCs (2.5× 105/well) plus rhIL-2 (100 U/ml), and 10ng/ml SRL for 5 d. 
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At the end of culture, the cells were harvested, and the surface expression of CD25, 
CD127, CTLA-4, CD45RO and intracellular expression of FOXP3, CTLA-4 and IL-10, 
TGF- were analyzed by flow cytometry. Numbers in the corners indicate the 
percentage of positive cells. Representative data are shown.  
B. SRL-derived Tregs were anergic to alloantigenic stimulation. CD4+CD25− responder 
T cells (Tresp) and SRL-derived CD4+CD25+CD127−/low cells (Tregs) were co-cultured 
with irradiated allogeneic D-PBMCx or a third-party 3rd-PBMCx at a ratio of 1:2, 
respectively. After 5 d of culture, T cell proliferation was determined using [3H]-
thymidine incorporation (n=3).  
 
3.9 DNA demethylation plays a role in the stability of FOXP3 
expression  
Recently, compelling evidence demonstrated that epigenetic 
regulation played a crucial role for establishment of a stable Treg lineage 
(Huehn, Polansky et al. 2009). Epigenetic modifications, which can target 
histones or the DNA directly, affect gene transcription by altering the 
accessibility of distinct DNA regions to transcription factors and other 
DNA-binding molecules. In an in vitro TGF-β-dependent conversion of 
iTreg cell model, Daniel et al demonstrated that the stabilizing effect of 
everolimus, a rapamycin-derivative on FOXP3 expression is partially 
produced by interfering with the expression of DNMT1 (Daniel, 
Wennhold et al. 2010), a DNA methyltransferase 1 involving the 
modification of DNA methylation in the Foxp3 locus (Baron, Floess et al. 
2007; Janson, Winerdal et al. 2008; Huehn, Polansky et al. 2009). The 
ablating DNMT1 gene, or knocking down by siRNA, or pharmacologic 
inhibition of DNMT1 activity markedly increased the efficacy of 
induction and stability of Foxp3 expression (Huehn, Polansky et al. 2009; 
Josefowicz, Wilson et al. 2009). We wanted to check whether SRL vs. 
TAC also had a similar effect on DNMT1 changes and accounted for its 
role in the induction of FOXP3 expression. 
As shown in Figure 7A, activated CD4
+
CD45RA
−
 T cells treated with 
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anti-CD3 and autologous APCs in SRL group, showed significantly lower 
levels of DNMT1 expression compared to untreated control or TAC 
treated group by western blot with bulk or total CD4
+
 T cells. This result 
was further confirmed with intracellular staining of DNMT1 protein by 
flow analysis. SRL, compared to the untreated control or TAC group, 
decreased about 26% of DNMT1 expression with PI3K inhibitor 
LY294002, which has strong and broad inhibition at the upstream of 
PI3K signaling, and decreased even more by 50% that of the control (Fig. 
13B). To take the advantage of flow technique, we gated on 
FOXP3
+
CD127
− 
Treg vs. FOXP3
−
CD127
+
 non-Treg subsets. 
Unexpectedly, we found that FOXP3+ cells contained higher baseline 
expression of DNMT1 vs. FOXP3
−
 cells. However, the expression of 
DNMT1 by SRL was sharply decreased in FOXP3+ cells vs. FOXP3- 
cells after culture treated with SRL for 5 days (35% vs. 20%, 
respectively), whereas TAC had no effect on DNMT1 expression in both 
populations. As a positive control, the levels of DNMT1 expression 
decreased the most at the above conditions treated with LY294002 
(potent inhibitor of phosphoinositide 3-kinases (PI3Ks) (Fig. 13C).   
From these findings, it is suggested that, in humans, weak downregulation 
of DNMTs by treatment with TGF-β and IL-2 minimally affects the 
maintenance of CpG methylation during cell division (proliferation), 
whereas strong downregulation of DNMTs by treatment with mTOR 
inhibitor, together with TGF-β/IL-2, suppresses the maintenance of DNA 
methylation, as such resulting in a gradual accumulation of the FOXP3
+
 
population. 
Whereas this result cannot prove a direct de novo induction of FOXP3+ 
cells from SRL treatment, we started out to check other possibility of SRL 
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related to de novo induction of FOXP3+ expression. We were particular 
interested in PI3K/AKT signaling in the induction of Tregs (Ouyang, W., 
O. Beckett, et al. 2010) as more recent data showed that PI3K/AKT/Foxo 
signaling plays a role in the development of thymic-derived natural Tregs 
and the de novo induction of TGF-β-induced iTregs (Ouyang, W., O. 
Beckett, et al. 2010) although PI3K/AKT/mTOR signaling has been 
recognized as a consistent defect in mouse and human CD4
+
CD25
+
 Treg 
cells compared to conventional T cells (Crellin, Garcia, et al. 2007). 
Although we observed a profound decrease in levels of phospho-AKT 
(Ser473) and phospho-FOXO3a by PI3K inhibitor LY294002 whereas 
SRL or TAC treatment showed no changes on either phospho-AKT or 
phospho-FOXO3a in alloreactive CD4
+
CD45RA

 T cells (data not 
shown). We concluded that SRL might not use PI3K/AKT/Foxo pathway 
as a potential de novo induction of FOXP3
+
 Tregs in alloactivated CD4 T 
cells. However, our results suggested a possible superior usage of a 
combined allosteric mTOR inhibitors with a dual PI3K/mTOR kinase 
inhibitor for the future design of transplantation tolerance induction drugs 
and the importance of Tregs in alloimmune inhibition.   
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Figure 13. SRL-mediated down-regulation of DNA methylation increased FOXP3 
stability.  Alloreactive CD4+CD45RA- T cells were re-stimulated with anti-CD3 and 
autologous APCs plus IL-2 in the presence or absence of 10 ng/ml SRL, 2ng/ml TAC or 
20 µM of LY294002 for a total of 5 days.  
A. DNMT1 expression was assessed at the end of the culture by Western blot analysis. 
Cell lysates from cultured cells as described above were separated by SDS/PAGE gel 
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and probed with primary polyclonal anti-DNMT1 followed by HRP-conjugated 
secondary antibody. SRL effectively decreased DNMT1 protein expression while TAC 
had no effect. Positive control of PI3K inhibitor (LY) showed profound inhibition of 
DNMT1 expression.  
B. DNMT1 expression was alternatively assessed by flow cytometry assay. At the end of 
culture, cells were recovered and intracellular expression of DNMT1 was first stained 
with a rabbit polyclonal anti-DNMT1 antibody followed by PE-conjugated anti-rabbit 
Ig. Total CD4+ cells were gated for analysis. Mean fluorescein intensity (MFI) changes 
compared to the control were calculated as: % of change = (control group - drug 
group)/control group. Comparable results were obtained compared to the western blot 
analysis.  
C. Flow-based DNMT1 expression was further analyzed by gating on CD4+CD127-
FOXP3+Tregs or CD4+CD127+FOXP3- non-Treg effector T cell subsets, respectively. 
Compared to effector T cells, Tregs showed profound decrease of DNMT1 expression 
with SRL treatment (35% vs. 20% decrease of MFI) whereas TAC had no changes, LY 
as a positive control.  
 
 
 
 
 
 
 
 
 
Discussion 
 
61 
 
DISCUSSION/CONCLUSIONS 
4.1 Discussion 
This study confirmed that allogeneic stimulation of human naïve T 
cells promote the differentiation of CD4
+
 T helper cells (Th1, Th17 and 
Treg cells). The results revealed that polyclonal activation of alloreactive 
T cells induced differentiation/expansion of effector Th1, Th17 and Treg 
cells, but the generation of alloreactive Th17 cell was dependent on the 
presence of APCs under neutral conditions or relatively physiologic 
stimulation. In addition, the findings indicated that alloreactive Th1 and 
Th17 cells were differently but effectively inhibited by calcineurin, and 
the component constitutions of proinflammatory Th1, Th17 cells and 
disease protective Treg cells had been changed. Moreover, this study 
confirme and extend also the previously proposed view that the Treg 
phenotype was not terminally differentiated (Zhou, Ivanov et al. 2007), 
and in the presence of SRL, FOXP3
+
 expression in Treg cells was stable 
and sustained its normal functional suppression to conventional CD4 T 
cell proliferation and Th1/Th17 allloimmunity. Furthermore, SRL 
increased the percentage of FOXP3
+
Tregs without promoting Treg 
reprogramming to increase FOXP3
+
IFN-γ and FOXP3+IL-17+ Treg 
subsets, and that the combination of SRL and very low dose of TAC 
completely inhibited phenotypic FOXP3
+
IFN-γ+ and FOXP3+IL-17+ Treg 
subsets. Mechanistically, TAC blocked TCR-induced calcineurin 
differently prohibiting the generation of Th1 and Th17 cells, and SRL 
stabilized Treg cells by inhibiting DNA methyltransferase without 
prominent affecting FOXO3/FOXP3 interaction.   
In this study, two different categories of immunosuppressive agents, 
calcineurin inhibitor (TAC) and mTOR inhibitor (SRL), were tested on 
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the generation of Th1, Th17 and Treg cells and the functional properties 
of in vitro generated Treg cells in activated alloreactive CD4 T cells. With 
regard to differential mechanisms, it becomes clear that Treg induction is 
best achieved by subimmunogenic TCR stimulation under conditions that 
avoid fully functional activation of antigen presenting cells, and the latter 
is also required for maximal differentiation of Th17 cells (Apostolou et al. 
2005; Evans, Suddason et al. 2007; Sauer, Bruno et al. 2008; Gottschalk, 
Corse et al. 2010). In fact, in a steady state without inflammation or acute 
rejection to transplants, the in vivo protocol was more akin to an in vitro 
conversion method where T cells were limited for subimmunogenic 
stimulation and a short time activation period in the absence of 
exogenously TGF-β and limited activation of the PI3K/AKT/mTOR 
pathway (Sauer, Bruno et al. 2008). In this system, the 
differentiation/expansion of generated alloreactive CD4 T cells (referred 
as monocyte/T cell culture) was inducted with subantigenic dose of anti-
CD3 stimulation (e.g. 100ng/ml) in the presence of unstimulated APCs 
for maximal induction of Treg and Th17 cells. High amount of IL-2, 
Foxp3 stabilization mediator (~ 100U/ml for human Treg induction) was 
included in the system (Davidson, DiPaolo et al. 2007; Horwitz, Zheng et 
al. 2008; Chen, Kim et al. 2011). 
The two immunosuppressive agents, TAC and SRL, were compared for 
their ability to block the transplant destructive effector Th1/Th17 cells 
and maintain the stability of FOXP3 expression in graft protective Treg 
cells. In the past two decades, a large array of immunosuppressive agents 
has expanded the armamentarium used by transplant physicians and 
surgeons to prevent acute allograft rejection, evidenced by the greatly 
improved rates of short-term graft survival. The focus of transplantation 
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medicine is now more shifted towards tackling issues associated with side 
effects of long-term immunosuppression and chronic rejection. TAC and 
SRL are widely used to effectively prevent transplant rejection. However, 
the effects of SRL and TAC on the subsets of alloreactive T cells, effector 
Th1/Th17 versus Treg cells, were not fully studied. 
The data showed that TAC and SRL in concentrations comparable or 
even lower than in vivo therapeutic concentrations, still strongly inhibited 
the proliferative capacity of human alloantigen-activated CD4 Th cells in 
vitro, not only at relatively to physiologic conditions, but also at stringent 
pro-inflammatory environments. Averagely over 90% of both IFN-γ, 
IL17-producing cells were blocked by TAC, and a relatively lower 
percentages (30 to 60% inhibition, respectively) affected by SRL. 
Interestingly, the presence of high concentration of IL-2 (e.g. 100U/ml) 
reversed the SRL effects on IFN-γ-secreting cells, but had little effect on 
IL-17
+
 cells. In the presence of inflammatory cytokines, such as IL-1b, 
IL-6 and TNF-a, TAC still effectively blocked Th1 and Th17 cell 
responses, while SRL only at high concentration (>10 ng/ml) or above the 
in vivo therapeutic concentrations could significantly inhibit IFN-γ or IL-
17 production. However, the combinations of low dose of TAC irreverent 
of concentrations of SRL effectively inhibited IFN-r or IL-17 production 
than SRL used alone. 
In this study, the capability of these two different categories of 
immunosuppressive drugs for the induction of alloantigen specific Tregs 
was tested. Consistent with previous work, SRL effectively induced 
alloantigen specific Tregs while TAC did not (Coenen, Koenen et al. 
2006; Gao, Lu et al. 2007; Strauss, Whiteside et al. 2007). Considering 
that SRL promote while TAC decrease both percentage and FOXP3 
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mRNA levels of FOXP3
+
 expression in alloreactive CD4 T cells (Figure 
10C), we conclude that in the presence of high amount of IL-2, TAC at 
2ng/ml with SRL at 2-5ng/ml achieved the maximal effect in inhibiting 
the production of IFN-γ and IL-17 while maintaining a high level of 
FOXP3 expression in alloreactive CD4 T cells. 
Although Th cell subsets preferentially express particular transcription 
factors and produce distinct cytokines, recent studies suggest considerable 
levels of plasticity between different T cell lineages and in vivo 
reprogramming of adaptive transferred Treg cells exist, and these point 
toward potent peripheral regulation of effector T cell subset development 
in a specific microenvironment (O'Shea and Paul 2010). For instance, 
peripheral mature Treg cells can be converted into IFN-γ-secreting Tregs 
(IFN- γ +FOXP3+) or completely Th1 cells or IL-17-secreting Tregs (IL-
17
+
FOXP3
+
) or completely Th17 cells in the presence of Th1 polarizing 
cytokine IL-12 or Th17 cytokines IL-1b or IL-6, respectively (Beriou, 
Costantino et al. 2009). In addition, proinflammatory conditions also 
promote reprogramming of Tregs (Kryczek, Wu et al. 2011). 
Functionally, although IL-17
+
Foxp3
+
 or IFN- γ +FOXP3+ T cells retained 
their suppressive capacity, they were not as strong as IL-17
-
FOXP3
+
 or 
IFN-γ-Foxp3+ Treg cells. They express moderate levels of effector 
cytokines and shared the trafficking phenotype with Treg and Th1 or 
Th17 cells, and may home to and play conventional T cell roles in the 
local microenvironment, or when encounter with several local 
proinflammatory stimuli, they may be able to reprogram themselves for  
its needs (O'Shea and Paul 2010). 
In addition to the inflammatory cytokines, immunosuppressive agents and 
epigenetic factors may also influence the plasticity of T cell subsets. A 
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recent study showed that at high concentration (>100ng/ml), SRL not 
only completely inhibited the differentiation of IFN-γ-secreting T cells, 
but also inhibited Foxp3
+
 Treg cells to produce inflammatory cytokines 
(IFN-γ or IL-17) when compared to untreated controls  (Hippen, Merkel 
et al. 2011; Hippen, Merkel et al. 2011). At a mimic physiologic 
environment or a non-polarizing condition, clinically therapeutic dose of 
SRL (e.g. 5ng/ml) were effectively induced functionally alloantigen 
specific Tregs without increasing any IFN-γ+FOXP3+ or IL-17+ 
FOXP3
+
Treg subsets, and importantly, when combined with very low 
dose of TAC, SRL-derived Tregs were completely spared of any these 
Treg subsets. Taken together, these data suggested that although the 
likelihood of plasticity and in vivo reprogramming of Tregs may be 
context-dependent, the in vitro manipulation of Treg cells with SRL or 
modifications of TSDR demethylation (SRL itself affects FOXP3 locus 
demethylation, (Fig. 13) of these cells may provide some degree of 
resistance to the reprogramming process and favor for in vivo stability of 
any therapeutic application of Tregs (Daniel, Wennhold et al. 2010; 
Hippen, Merkel et al. 2011). 
Further analysis established that SRL-derived Tregs were real Tregs, 
which expressed typical Treg surface markers, were anergic to 
allostimulations, and most importantly they specifically suppressed 
proliferation of allogeneic effector T cells and Th1 and Th17 alloimmune 
responses. SRL-derived Tregs also expressed TGF-β and IL-10, two 
important anti-inflammatory cytokines in limiting inflammatory 
responses and the generation of Treg cells. TGF-β alone plays a critical 
role in the induction and homeostasis of Treg cells, whereas in the 
presence of inflammatory cytokines, it promotes Th17 differentiation, but 
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this TGF- β comes from activated T cells, but not from Treg cells. This  
suggests that Treg-derived anti-inflammatory cytokines TGF-β and IL-10 
are important for promoting tolerance induction while constraining 
proinflammtory Th17 immunity, although SRL moderately reduced Treg-
derived IL-10 production in our study.  
The stability of FOXP3 expression appeared mandatory for the induction 
of prospective tolerance, and the in vitro induction of iTreg with unstable 
Foxp3 expression is correlated with lack of demethylation of the Foxp3 
locus, (Baron, Floess et al. 2007; Janson, Winerdal et al. 2008; Huehn, 
Polansky et al. 2009). The ability of SRL and TAC to maintain the 
stability of FOXP3 expression was compared. SRL significantly 
decreased DNMT1(FOXP3 promoter demethylation) expression, which 
may be is a prerequisite for stable FOXP3 expression and suppressive 
phenotype of Tregs (Huehn, Polansky et al. 2009).  The above results 
revealed that SRL more than TAC might interfere with the DNMT1 
expression, and this underlined its appropriately future therapeutic 
strategies as Treg cells target.  
The molecular basis of mTOR inhibitors such as SRL and everolimus 
increasing FOXP3 expression is presently largely unknown (Ouyang W, 
Beckett O, natimm2010) 
Although the results in this study showed a profound decrease in levels of 
phospho-AKT and phosphor-FOXO3a in PI3K inhibitor LY294002 
treated group, there was no evidence of either SRL or TAC has any effect 
on the phosphorylation of these two proteins. We concluded that SRL 
might not use PI3K/AKT/FOXO pathway as a potential de novo induction 
of FOXP3
+
 Tregs, and any further efforts to delineate the underlie 
mechanism are encouraged. These results also suggested a possible 
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superior usage of a combined allosteric mTOR inhibitors with a dual 
PI3K/mTOR kinase inhibitor for the future design of transplantation 
tolerance induction drugs.   
In sum, SRL and TAC differentially affect differentiation/expansion of 
alloreactive pathogenic Th1 and Th17 cells and graft-protective Treg 
cells. TAC used at lower than clinically therapeutic dose is more effective 
than SRL for inhibiting Th1 and Th17 cells, whereas SRL has advantage 
for de novo induction and expansion of donor-specific and functional 
Treg cells. Therefore, the combination of SRL and TAC should be 
considered for tolerance-inducing protocols, in order to recruit not only 
natural, but also induced FOXP3
+
 cells into the overall Treg pool while 
still effective controlling the graft-destructive effector Th1 and Th17 
cells. The appropriate amount of the combination of SRL and TAC used 
for clinical transplant patients should contribute relatively to a better 
tolerance induction while warrant effectively blocking acute rejection. 
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